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The recent global spread of carbapenemase genes is an emerging problem. The 
aim of this thesis was to identify the reasons behind the increase in 
carbapenem-resistance in Gram-negative bacilli in Singapore. While multiple 
factors probably contribute to this emergence in Singapore, this thesis 
hypothesised that the introduction of global clones of carbapenemase-
producing strains with the potential to cause outbreaks is an important reason.  
This hypothesis was tested in Pseudomonas aeruginosa, Acinetobacter 
baumannii, and Enterobacteriaceae. 
 
The first layer of molecular typing used a discriminatory fingerprinting 
method to determine the presence of clones within the local population of 
isolates. From the fingerprinting data, representative isolates were selected for 
a second layer of typing using MLST and AFLP™.  
 
Major findings regarding acquired carbapenemases in P. aeruginosa 
In 2000, 21 of 2,094 non-duplicate P. aeruginosa had metallo-β-lactamase 
(MBL) genes. With the exception of 1 isolate with blaIMP-7, all other isolates 
had blaIMP-1 and belonged to one of two clones. These 2 clones were not 
international outbreak clones and did not emerge dominant in 2008. Of 2,552 
non-duplicate P. aeruginosa isolated in 2008, 9 yielded a product by multiplex 
PCR for MBL genes. The 2008 isolates were quite heterogenous with blaVIM-2 
and blaVIM-6 emerging in P. aeruginosa for the first time in Singapore. 
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International clones belonging to CC235 appeared in 2008 and contained a 
mix of MBL genes. 
 
Major findings regarding acquired carbapenemases in the Acinetobacter 
calcoaceticus-Acinetobacter baumannii species complex (Acb) 
One hundred and ninety-three non-duplicate Acb were collected over a 1-
month period from 6 hospitals in 2006. A high proportion of Acb were 
resistant to carbapenems (63.7%). Most carbapenem-resistant A. baumannii 
and Acinetobacter nosocomialis possessed the blaOXA-23-like gene. Most 
carbapenem-resistant Acinetobacter pittii had the blaOXA-58-like gene. In an 
earlier study carried out in 1 hospital, 7.7% of Acb collected in 1996, and 
21.2% of Acb collected in 2001, were resistant to carbapenems. The main 
outbreak isolates of carbapenemase-producing A. baumannii in 1996 did not 
belong to international outbreak clones. Outbreak isolates from 2001 belonged 
to European clones I and II. One of these clones could still be found among 
isolates collected in 2006.  
 
Major findings regarding acquired carbapenemases in Enterobacteriaceae  
Since the first isolate of carbapenemase-producing Enterobacteriaceae in 
Singapore in 1996, we have collected a further 40 isolates. The only large 
outbreak clone was blaOXA-181-positive Klebsiella pneumoniae belonging to 
ST14. Even though K. pneumoniae with blaKPC-2 were not clonal by PFGE, 
they all belonged to ST11.  
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Global clones are present among carbapenemase-producing P. aeruginosa, A. 
baumannii, and Enterobacteriaceae in Singapore. They are likely to be 
responsible for the increase in carbapenem-resistant A. baumannii but not P. 
aeruginosa. However, the global clones of carbapenemase-producing P. 
aeruginosa and Enterobacteriaceae are recently introduced and the situation 
may change in the future. These findings demonstrate the diversity of acquired 
carbapenemase genes in Singapore, their distribution among different species, 
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Chapter 1 Introduction and Literature Review 
 
The β-lactam antibiotics 
The discovery of penicillin by Alexander Fleming in 1928, its purification by 
Florey and others at the Sir William Dunn School of Pathology in Oxford, and 
the success of mass production methods in corporate North America have 
changed our perspective of infectious diseases forever (1). While other 
antibacterial chemicals like the sulphonamides already existed, penicillin had 
much greater potency against many important bacterial pathogens and had 
relatively minor side effects apart from the occasional hypersensitivity 
reaction.   
 
Introduced into large scale use during the Second World War, penicillin was 
able to treat infected wounds and burns, thereby saving countless lives that 
would otherwise have succumbed to gas gangrene and the streptococcal 
infections that had plagued previous generations of injured soldiers. Away 
from the battlefield, venereal diseases like gonorrhoea and syphilis that often 
accompany warfare were also highly susceptible to the new drug. Once the 
war ended, penicillin found utility treating pneumonia and meningitis, roles it 
continues to perform to this day.  
 
The first cephalosporin was discovered by Giuseppe Brotzu in 1945 (2). Like 
Fleming before him, Brotzu lacked the ability to extract and purify his 
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antibiotic. This was left to scientists at the aforementioned Sir William Dunn 
School of Pathology.  In 1953, cephalosporin C was discovered by Newton 
and Abraham (3). Together with penicillin, these proved to be the forerunners 
of a most versatile family of compounds with potent and specific antibacterial 
activity. 
 
Both the penicillins and the cephalosporins have a β-lactam ring. In the case of 
penicillin, this is fused to a 5-membered thiazolidine ring and in the case of 
the cephalosporins a six-membered dihydrothiazine ring. Modifications of the 
basic structure by adding different side chains resulted in derivative drugs with 
new properties. The poor activity against Gram-negative bacilli that was a 
feature of the original penicillin was overcome by adding an amino group to 
give ampicillin (4). However as early as 1940, an enzyme had been discovered 
that was able to hydrolyze the β-lactam ring of penicillin (5). This was to be 
but the first of a multitude known collectively as β-lactamases. These enzymes 
are related at a structural and functional level to the penicillin-binding proteins 
involved in bacterial cell wall synthesis (6). β-lactams may be  substrates or 
inhibitors for both β-lactamases and penicillin binding proteins. The difference 
is that β-lactamases hydrolyze β-lactams at a much higher rate than penicillin 
binding proteins (7).  
 
The first β-lactamases were essentially penicillinases found in staphylococci 
(8) and Bacillus spp. (9).  In the latter part of the 1970s, β-lactamases with the 
ability to hydrolyze broader spectrum β-lactams including ampicillin began to 
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spread.  This included the TEM-1, SHV-1, and OXA-1 plasmid-borne β-
lactamases found in many Enterobacteriaceae (10). Pharmaceutical 
companies responded with cephalosporins like cefuroxime, the first to 
demonstrate stability to the new β-lactamases (11). This was followed by 
oxyimino-cephalosporins like cefotaxime (12) and ceftazidime (13) with even 
more potent activity against Gram-negative bacilli.  However as the use of 
these extended-spectrum cephalosporins became more widespread, it 
promoted the emergence of a corresponding generation of extended-spectrum 
β-lactamases (ESBLs). Most of these were point mutations of the 
aforementioned TEM, SHV and OXA plasmid-borne β-lactamases. In 
addition, many Gram-negative bacilli also intrinsically produced a 
chromosomal cephalosporinase (AmpC) able to hydrolyze extended-spectrum 
cephalosporins. These enzymes are usually not produced unless induced but in 
certain species like Enterobacter cloacae and Citrobacter freundii, mutations 
may occur in the regulatory genes with high frequency allowing the enzymes 
to be constitutively hyper-produced in large quantities. Cephalosporinases 
have also mobilized onto plasmids (pAmpC) and spread to 
Enterobacteriaceae other than their species of origin. 
 
The carbapenems 
This preamble illustrates the amount of human effort that went into the 
development of this most useful group of antimicrobials and how at every turn 
the bacteria have been able to mount an appropriate response. The increasing 
resistance to penicillins and cephalosporins as a result of β-lactamases led to 
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some drug companies to screen soil actinomycetes for solutions. In the 
intervening years since the dawn of the age of antibiotics, drug discovery had 
become less likely to result from individual endeavour. In the 1970s, while 
looking for a β-lactamase inhibitor, researchers at Beecham Research 
Laboratories identified the olivanic acid complex from Streptomyces olivaceus 
(14). Almost simultaneously, thienamycin was being independently isolated 
by scientists at Merck from a strain of Streptomyces cattleya (15).  These 
compounds differ from other β-lactams by having a carbon atom instead of 
sulphur in the fused ring structure. Merck scientists were eventually able to 
produce a N-formimidoyl derivative of thienamycin that overcame the 
inherent  instability of the natural antibiotic. This resulted in imipenem, the 
first commercially available carbapenem which was launched in the late 
1980s. 
 
Imipenem delivered unprecedented activity against a broad spectrum of 
bacterial pathogens including Gram-positive bacteria and anaerobes. However 
it is against Gram-negative bacilli including Pseudomonas aeruginosa and 
Acinetobacter spp.  that imipenem has found its main raison d’etre. This is 
because imipenem retains stability against extended-spectrum and AmpC β-
lactamases. There remain a few issues with imipenem. Firstly, imipenem is 
hydroylzed by dehydropeptidase I which is naturally found in the kidney. 
Consequently imipenem has to be administered with a dehydropeptidase 
inhibitor called cilastatin.  Imipenem is also perceived to be more prone to 
provoke seizures. This is thought to be related to the structure of the C-2 side 
chain which may interact with the γ-aminobutyric acid (GABAA) receptor 
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(16). Imipenem needs to be administered three or four times a day depending 
on the dose. It is not absorbed orally and therefore has to be given 
intravenously (17). Newer carbapenems are all attempts to overcome some of 
these problems. 
 
Panipenem was introduced by Sankyo in 1993. However it still required a 
dehydropeptidase inhibitor, in this case betamipron (18).  It does not offer any 
advantages over other presently available carbapenems and is virtually 
unknown outside the Japanese market.  
 
Sumitomo Pharmaceuticals introduced the first commercial dehydropeptidase 
stable carbapenem when meropenem was launched in 1995. Meropenem is 
slightly more active against Gram-negative bacteria and slightly less active 
against Gram-positive bacteria in-vitro (19). It is also less prone to cause 
seizures compared with imipenem. 
 
Merck launched ertapenem in 2002. This is excreted less quickly allowing for 
once-daily dosing. However, ertapenem has no clinically useful activity 
against P. aeruginosa and Acinetobacter spp. (20). 
 
Of the remaining available carbapenems, biapenem resembles meropenem in 
its stability to dehydropeptidase and activity against Gram-negative bacteria 
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but is not widely used (21). Doripenem was launched in 2005 and also 
resembles meropenem in activity. In vitro studies show that doripenem may be 
less selective for resistant P. aeruginosa mutants compared with other 
carbapenems (22). Faropenem and ritipenem  are penems that are similar in 
structure to carbapenems except that they have a sulphur in the β-lactam ring 
instead of carbon. They can be administered orally (23). 
 
Because of their broad spectrum of antimicrobial activity and their stability to 
hydrolysis by most Gram-negative β-lactamases, the carbapenems have 
become the treatment of choice against multidrug-resistant Gram-negative 
bacilli, and as empirical therapy in critically ill patients with severe healthcare-
associated infections. 
 
Carbapenem resistance in Gram-negative bacilli 
Carbapenem resistance may arise in Gram-negative bacilli via a number of 
different mechanisms. Acinetobacter spp. may develop reduced susceptibility 
to carbapenems because of alterations in the penicillin-binding protein targets 
(24). In P. aeruginosa, specific resistance to imipenem may result from 
impermeability due to diminished expression of the OprD porin (25). Reduced 
susceptibility to carbapenems in general may also arise in this species as a 
result of up-regulated efflux through the MexA-MexB-OprM pump (26). 
However, these mechanisms are intrinsic to each individual strain and the 
resistance is not transferable. Enzymes with specific hydrolytic activity (β-
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lactamases) represent the most potent threat to the β-lactam antibiotics because 
they are able to confer much higher levels of resistance and the genes are 
potentially transferable. In reality, a combination of mechanisms may be 
responsible for the final antimicrobial resistance phenotype (27). 
 
β-lactamase classification 
There are currently several hundred different β-lactamases described.  Variants 
of the original TEM and SHV alone number 205 and 168 respectively 
(http://www.lahey.org/Studies/ accessed on 29 December 2012).  Two systems 
exist to classify β-lactamases.  A functional scheme relies on the hydrolysis 
and inhibition profile of the enzyme (28), whereas a structural scheme is based 
on the molecular structure (29). As the number of β-lactamases increased in 
number and complexity, the structural classification by Ambler has largely 
superseded the latter on account of its logic and simplicity. This scheme 
divides the β-lactamases into 4 classes labelled A to D. There is some 
correlation with the functional classification.  Classes A, C, and D have a 
serine at their active site.  Class A β-lactamases may be penicillinases and/or 
cephalosporinases that are inhibited by clavulanic acid. Class D (OXA) β-
lactamases are a  very diverse group that are defined by their ability to 
hydrolyze oxacillin at a higher rate than penicillin, a property not seen in most 
class A and class C β-lactamases. They lack a specific inhibitor. Class C β-
lactamases are cephalosporinases that are inhibited by cloxacillin. Class B β-
lactamases are carbapenemases that are also known as metallo-β-lactamases 
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(MBL) because they require zinc ions at the active site and are therefore 
inhibited by metal-chelators. 
 
Constitutive carbapenemases 
Given that carbapenems are derived from natural products, it is not surprising 
that a few species of bacteria naturally produce carbapenemases in their wild 
state.  Some are not clinically significant, like FEZ found in Fluoribacter 
(formerely Legionella) gormani (30). Others are Gram-negative bacilli that 
have low pathogenicity but may occasionally cause true infections that are 
difficult to treat because of intrinsic multidrug resistance. These include 
Stenotrophomonas maltophilia and Elizabethkingae meningosepticum that 
produce L1 (31), and GOB and BlaB (32) respectively. While problematic at 
the level of the individual patient, these constitutive carbapenemases present a 
limited threat at a global level. This is because the carbapenemase gene is on 
the chromosome and is not on a transferable element that may enable its 
spread to other potentially more pathogenic bacteria.  
 
Acquired carbapenemases 
The first plasmid-encoded carbapenemase was a class B enzyme called IMP-1, 
that was first described in Serratia marcescens in Japan in 1994 and 
subsequently found to have also spread among P. aeruginosa (33). The next 
family of plasmid-encoded class B enzymes were the VIM-type enzymes first 
described in P. aeruginosa in Italy in 1997 (34). Whereas IMP-1 and its 
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variants are found predominantly in Asia, VIM-type enzymes dominate in 
Europe particularly in Italy (35) and Greece (36). With 42 variants of IMP and 
37 variants of VIM (http://www.lahey.org/Studies/ accessed on 29 December 
2012) spread across 6 continents they have become the dominant class of 
carbapenemase in the last decade. A number of other plasmid-borne class B β-
lactamases have since emerged but have remained relatively limited in their 
distribution. Recently a new class B enzyme has emerged from the Indian 
subcontinent.  The gene encoding this new enzyme, blaNDM-1,  has spread at an 
unprecedented rate and the plasmids bearing the gene have demonstrated the 
ability to be easily transferred to other bacteria (37). 
 
Following IMP and VIM, the next plasmid-associated carbapenemase to 
achieve international prominence was a class A enzyme. Class A 
carbapenemases were in fact some of the earliest carbapenemases to be 
discovered.  SME-1 from S. marcescens isolated in London in 1982 (38) and  
IMI-1 from  2 E. cloacae isolated in a California hospital in 1984 (39) were 
both discovered  before imipenem was introduced. The similar NMC-A was 
first described from an E. cloacae isolated in Paris in 1990 (40).  Unusually, 
these enzymes hydrolyze carbapenems more strongly than oxyimino-
cephalosporins. They were not found on transferable elements and remain 
rare. However in 1996, a carbapenem-resistant Klebsiella pneumoniae was 
isolated in North Carolina that produced a novel plasmid-associated class A 
carbapenemase (originally called KPC-1 but now revised to KPC-2) (41). The 
KPC family of carbapenemases presently number 13 variants 
(http://www.lahey.org/Studies/ accessed on 30 December 2012).  Unlike 
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earlier, class A carbapenemases, KPC also strongly hydrolyzes oxyimino-
cephalosporins. KPC producers  have since spread along the eastern United 
States and have also been found overseas in Europe, Columbia, Israel  and 
China largely as the result of spread of a particular clone designated ST258 by 
multilocus sequence typing (MLST) (42). 
 
OXA carbapenemases were first found in the Acinetobacter calcoaceticus-
Acinetobacter baumannii species complex (Acb) and most of them are still 
confined to that species complex. The gene for OXA-51-type enzymes 
(blaOXA-51-type) is native to the chromosome of A. baumannii (43). On the other 
hand blaOXA-23, -24 and -58-types are acquired and may be found on plasmids (44-
46). Of these, blaOXA-23-type is largely responsible for the worldwide emergence 
of carbapenem-resistant A. baumannii and has been found in isolates dating 
back to 1985 (47). OXA-48 was first identified in K. pneumoniae in Turkey in 
2003 (48). It remains the major cause of outbreaks of carbapenem-resistant 
Enterobacteriaceae in Turkey. OXA-48 producers have since spread to 
Europe and northern Africa (42). A new variant, OXA-181 has recently been 
found in India and, if the experience with NDM-1 is any precedent, seems 
likely to spread further abroad (49). 
 
Taken together, the recent global spread of carbapenemase genes threatens the 
utility of this critical line of defence against multidrug-resistant bacilli and 
raises the spectre of a return to the age before antibiotics. 
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Mobilization of antimicrobial resistance genes in Gram-negative bacilli 
There are many mechanisms by which genes may be acquired and 
disseminated between Gram-negative bacilli, though not all of them are 
known to be involved in the spread of carbapenemase genes. Transformation 
is the process by which bacteria acquire naked DNA from their surroundings. 
Transduction is the transfer of DNA between bacterial cells via a 
bacteriophage. While Acinetobacter spp. are naturally transformable and β-
lactamase genes have been found on bacteriophages, both transformation and 
transduction are not normally thought to be significant mechanisms for the 
acquisition of resistance genes in Gram-negative bacilli (50, 51).  
 
Insertion sequences (IS) are genetic elements that encode a transposase which 
is responsible for their excision and insertion into chromosomes and plasmids. 
They are able to transfer genetic material by a number of mechanisms. Two IS 
may flank an antimicrobial resistance gene to form a composite transposon as 
in the case of Tn1999 and blaOXA-48 (52). A single IS may also be able to 
mobilize adjacent DNA such as ISEcp1 associated with blaOXA-181 (53). 
 
Conjugation is a process to transfer DNA that requires cell-to-cell contact. 
Plasmids are double–stranded DNA, usually circular, that are capable of 
replication independent of the bacterial chromosome. Conjugative plasmids 
are the most common vectors for antimicrobial resistance genes between 
bacterial cells and can transfer the largest amounts of DNA. It has been 
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observed that resistance genes seem to be moving from chromosomes to 
plasmids more rapidly than ever before and that plasmids seem to be 
aggregating more resistance genes (54). Plasmids belonging to certain 
incompatibility groups are known to be more successful at spreading 
resistance genes and within these groups the structure of the plasmid is 
relatively conserved (55). However, exactly what makes these plasmids more 
successful at spreading resistance genes than others remains unknown.   
 
Integrative and conjugative elements (ICEs) also mobilize genes by 
conjugation but unlike plasmids are not self-replicating and cannot exist 
independently of the chromosome (56). However, they have the ability to 
excise, initiate conjugation with a recipient cell and reintegrate into the new 
chromosome to be passed from one generation to the next. At the present time, 
no carbapenemase gene has been associated with ICEs. 
 
The genes encoding IMP and VIM are often found on integrons. These are 
genetic units that are able to collect small mobile elements called gene 
cassettes via site-specific recombination. They are characterized by an intI 
gene that encodes a site-specific recombinase IntI and an attI recombination 
site recognized by the IntI integrase. The gene cassettes contain the antibiotic 
resistance gene and an attC recombination site that allows them to be 
recognized by IntI.  Integrons are not mobile by themselves but may be 
associated with transposons and hence move onto plasmids (57). 
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Acquired carbapenem resistance in Gram-negative bacilli in Singapore 
Acquired carbapenemase genes were discovered in Singapore very soon after 
they were first described. A carbapenem-resistant K. pneumoniae producing 
IMP-1 was isolated from a haematology patient with no apparent history of 
travel in 1996. This was the first time IMP-1 had been described outside 
Japan, and Singapore became only the third country (after Japan and Italy) to 
report a plasmid-borne carbapenemase gene (58).  
 
Because blaIMP-1 had been found in P. aeruginosa in Japan, a study was carried 
out to determine if this gene was present in this species in Singapore (59). 
Between December 1999 and February 2001, 36 isolates of carbapenemase-
producing P. aeruginosa were collected. Pulsed-field gel electrophoresis 
(PFGE) showed that there were two clones. One clone had blaIMP-1 that was 
identical in sequence to that first reported in Japan. The other clone had a 
variant with four silent mutations. A single isolate had blaIMP-7. During the 
course of this study, four carbapenemase-producing fluorescent Pseudomonas 
spp. were isolated (60). One Pseudomonas putida had the original blaIMP-1 
sequence while a Pseudomonas fluorescens had the variant sequence. The 
remaining two P. putida isolates had identical PFGE patterns and produced a 
novel MBL, VIM-6, that differed from VIM-3 and VIM-2 by one and two 




Acb were studied next because they are often carbapenem-resistant and 
isolated together with P. aeruginosa from the same patients. One hundred and 
fourteen isolates of imipenem-resistant Acb were collected over two 5-month 
periods (in 1996 and 2001) (61). The incidence of carbapenemase genes 
approximately doubled (3.7% to 7.2%) between the two study periods. PFGE 
showed a number of clones which were essentially different during the two 
study periods. There was a clear demarcation in the distribution of acquired 
carbapenemase genes. Carbapenem-resistant A. baumannii had blaOXA-23 
whereas carbapenem-resistant Acinetobacter pittii and Acinetobacter 
nosocomialis had blaIMP-4 and blaOXA-58 (62). 
 
These early studies showed that clonal spread was occurring in these species. 
However the typing method employed did not allow comparison with clones 
in other countries. This was at a time when it was becoming apparent that 
spread of antimicrobial resistance worldwide was sometimes driven by 
specific international clones. In the meantime, new typing methods like MLST 
had been developed that allowed objective inter-laboratory comparison of 
strains and their evolutionary relationships (63).  
 
The impetus for this study was the increasing problem of carbapenem-
resistance among Gram-negative bacilli in Singapore. In a recent national 
survey, about 8% of P. aeruginosa clinical isolates in Singapore were resistant 
to carbapenems (64). The percentage of isolates of Acb that were resistant to 
carbapenems was even more alarming at about 65%. The percentage in cases 
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of bacteraemia was hardly better at 60% (65). This percentage of carbapenem 
resistance is one of the highest in the world. By comparison, carbapenem 
resistance in cases of Acinetobacter spp. bacteraemia in the United Kingdom 
in 2008 was around 15% (66). While carbapenem resistance among 
Escherichia coli and K. pneumoniae in Singapore was still too low to be 
expressed as a percentage, the absolute numbers appear to be on the increase 
(67, 68). Initially at least, most of the carbapenem resistance among 
Enterobacteriaceae was due to either pAmpC or CTX-M β-lactamases (69, 
70). Between 1996 and 2010, only one other carbapenemase-producing 
Enterobacteriaceae was isolated. This was another IMP-1-producing K. 
pneumoniae isolated in 2004. 
 
The aim of this thesis was to identify the reasons behind this increase in 
carbapenem resistance. The hypothesis was that the increase of carbapenem-
resistance in Gram-negative bacilli in Singapore may be the result of the 
introduction of clones of carbapenemase-producers that have demonstrated the 




Chapter 2: Acquired Carbapenemases in P. aeruginosa 
 
Introduction 
Carbapenem-resistant P. aeruginosa are an increasing problem worldwide. 
While many underlying mechanisms may account for carbapenem resistance 
in this species, the possession of MBL genes is of particular concern because 
these enzymes are able to hydrolyze all β-lactam antimicrobials with the 
exception of aztreonam.  In addition, these genes may be mobilized and 
transferred between different species of bacteria. We conducted a study in 
2008 to investigate if there were any changes in the epidemiology of P. 
aeruginosa isolates containing MBL genes in our hospital compared to an 
earlier survey carried out in 2000 (59). 
 
Materials and methods 
We studied  P. aeruginosa isolated in the Singapore General Hospital from 
patients with suspected clinical infections in 2008 that were imipenem-
resistant by CLSI criteria (71). 
 
Modified Hodge test 
Imipenem-resistant P. aeruginosa were screened for carbapenemase 
production by the modified Hodge test (72). A lawn of susceptible E. coli 
(ATCC 25922) was spread across a BBL
TM
 Mueller Hinton II plate (BD, 
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Maryland, USA) using a cotton swab impregnated with a suspension of the 
organism adjusted to one-tenth the turbidity of a 0.5 McFarland standard. 
After brief drying, a 10 µg imipenem disk (BD) was placed in the centre of the 
plate and test and control organisms were heavily streaked from the edge of 
the disk to the edge of the agar on the plate. The plate was incubated in air 
overnight at 35ºC. The following day, any growth of E. coli along a streak into 
the zone of inhibition around the imipenem disk was interpreted as probable 
carbapenemase production by the organism in the streak. K. pneumoniae 
DB44384/96 (blaIMP-1 positive) and P. aeruginosa ATCC 27853 were used as 
positive and negative controls respectively.  
 
Imipenem-EDTA disk diffusion 
Probable carbapenamease producers were tested for MBL production by the 
imipenem-EDTA disk diffusion test (73). A suspension of test isolate adjusted 
to match the turbidity of a 0.5 McFarland standard was inoculated onto a 
BBL
TM
 Mueller Hinton II plate (BD) with a cotton swab. Two 10 µg 
imipenem disks (BD) were placed onto the agar and 750 µg of EDTA was 
applied to one of the disks. EDTA is a metal chelator and therefore inhibits 
MBLs that rely on zinc ions at their binding site for their activity. An increase 
in diameter of the zone of inhibition around the imipenem-EDTA disk of ≥7 





Multiplex PCR for MBL genes 
Isolates that were likely to produce a MBL were tested for blaIMP, blaVIM, 
blaSPM-1, blaGIM-1 and blaSIM-1 using multiplex PCR (74).  
 
Table 1 Primers used in multiplex PCR for MBL genes. 
Gene Name Primer (5’-3’) 
blaIMP Imp-F GGAATAGAGTGGCTTAAYTCTC 
Imp-R CCAAACYACTASGTTATCT 
blaVIM Vim-F GATGGTGTTTGGTCGCATA 
Vim-R CGAATGCGCAGCACCAG 
blaGIM-1 Gim-F TCGACACACCTTGGTCTGAA 
Gim-R AACTTCCAACTTTGCCATGC 
blaSPM-1 Spm-F AAAATCTGGGTACGCAAACG 
Spm-R ACATTATCCGCTGGAACAGG 
blaSIM-1 Sim-F TACAAGGATTCGGCATCG 
Sim-R TAATGGCCTGTTCCCATGTG 
 
DNA was extracted by emulsifying a 1 µl loopful of bacteria in 100 µl 
InstaGene
TM
 Matrix (Bio-Rad Laboratories, Hercules, CA, USA). The mixture 
was heated to 100ºC for 15 min in a heating block to lyse the cells, and then 




The PCR reaction mixture was made up using the QIAGEN multiplex PCR 
Kit (QIAGEN GmbH, Hilden, Germany) and 2 µl of DNA extract in a final 
reaction volume of 25 µl.  
 
Multiplex PCR was carried out in a GeneAmp
®
 PCR System 9700 (Applied 
Biosystems, Foster City, CA, USA). The cycling conditions were: initial 
denaturation at 95ºC for 15 min, followed by 36 cycles of denaturation at 94ºC 
for 30 s, annealing at 52ºC for 40 s, and elongation at 72ºC for 50 s, followed 
by a final elongation step at 72ºC for 5 min. 
 
After the reaction was completed, the PCR products were mixed with 6X 
loading dye and loaded into a gel made from 2% SeaKem
®
 LE agarose 
(Cambrex Bio Science Rockland Inc, Rockland, ME, USA) in 0.5X Tris-
Borate-EDTA (TBE) buffer. A 100 bp DNA ladder (Promega Corporation, 
Madison, WI, USA) was used to size the products. Electrophoresis was carried 
out in a MINI-SUBCELL
®
 GT (BIO-RAD, Hercules, CA, USA) with power 
provided by a POWER PAC 300 (BIO-RAD) at a constant voltage of 110V 
for 50 min.  
 
The gel was stained in GelRed™ Nucleic Acid Gel Stain (Biotium, Hayward, 




Amplification and sequencing of MBL genes 
The entire MBL gene was amplified and sequenced from DNA extracts that 
were positive by multiplex PCR using the primers described by Chu et al (75) 
and Yan et al (76). 
 
Table 2 Primers used for amplification and sequencing of MBL genes. 



















The PCR reaction mixture was made up using the QIAGEN Taq PCR Master 
Mix Kit (QIAGEN) and 2 µl of DNA extract in a final reaction volume of 25 
µl. Amplification and sequencing were carried out in a GeneAmp
®
 PCR 
System 9700 (Applied Biosystems).  The cycling conditions were: initial 
denaturation at 94ºC for 3 min, followed by 35 cycles of denaturation at 94ºC 
for 1 min, annealing at 55ºC for 1 min, and elongation at 72ºC for 2 min, 
followed by a final elongation step at 72ºC for 7 min. 
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The PCR products were cleaned up using the QIAquick PCR Purification Kit 
(Qiagen) to remove residual nucleotides, primers and Taq polymerase. 2.5 µl 
of purified PCR product was added to 1.5 µl of diluted primer (approximately 
30 µM), 4 µl of ABI PRISM
®
 BigDye Terminator (Applied Biosystems) and 2 
µl of RNase-free water. The cycling conditions were: initial denaturation at 
96ºC for 3 min, followed by 25 cycles of denaturation at 96ºC for 10 s, 
annealing at 50ºC for 5 s, and elongation at 60ºC for 4 min. 
 
Absolute ethanol (25 µl ) and 1 µl 3M sodium acetate were added to the cycle 
sequencing products which were left at room temperature for 30 min to 
precipitate. After centrifugation at 12,000 rpm for 20 min, the supernatant was 
discarded. The pellet was washed with 125 µl of 70% ethanol and centrifuged 
again at 12,000 rpm for 10 min. After removing the supernatant, the pellet was 
re-suspended in 12 µl Hi-Di™ Formamide (Applied Biosystems). The 
prepared cycle sequencing products were denatured at 95ºC for 2 min using a 
GeneAmp
®
 PCR System 9700 (Applied Biosystems) before loading onto an 
ABI
®
 PRISM 3100 Genetic analyser (Applied Biosystems). 
 
The obtained sequences were edited and assembled using ChromasPro 
(Technelysium, South Brisbane, QLD, Australia) and compared with 






The clonal relationship between isolates with MBL genes was determined by 
PFGE of chromosomal DNA restricted with SpeI (59).  
 
Isolates of interest were cultured on tryptic soy agar containing 5% sheep 
blood (BD). After overnight growth in air at 35ºC, 1-5 colonies were picked 
and inoculated into 6 ml of tryptic soy broth and incubated overnight at 35ºC. 
 
Cells were harvested by centrifuging the broth culture at 2,800 rpm for 20 
min. the supernatant was discarded and the pellet re-suspended in 1 ml of PIV 
buffer (Appendix 1). The suspension was transfered to a microcentrifuge tube, 
and washed twice by centrifuging at 13,000 rpm for 2 min, discarding the 
supernatant, and re-suspending the pellet in 1 ml of PIV buffer. After the final 
wash, the pellet was re-suspended in 200 µl of PIV buffer by vortexing. The 
optical density of the suspension was measured at a wavelength of 620 nm 
using a GENESYS™ 10UV spectrophotometer (Thermo Spectronic, 
Rochester, NY, USA) and the final cell concentration adjusted to an optical 
density (O.D.) of 5.0 by adding PIV buffer. 
 





(FMC Bioproducts, Rockland, ME, USA)  held at 50ºC to 100 µl of the 
O.D.620 5.0 cell suspension in a microcentrifuge tube and mixing gently. The 
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mixture was dispensed into plug molds (BIO-RAD) and left to cool at 4ºC for 
30 min. 
 
The set gel plugs were carefully pushed out of the molds into individual wells 
of a six-well tissue culture plate containing 2 ml of EC lysis buffer (Appendix 
1) per well. 
 
The cells in the plugs were lysed by adding 10 µl of lysozyme (20 mg/ml) and 
10 µl of RNase (10 mg/ml) to each well and incubating at 35ºC for at least 3 h. 
The EC lysis solution was then aspirated with a Pasteur pipette and discarded. 
 
Contaminating proteins in the plugs was digested by adding 2 ml of ES buffer 
(Appendix 1) to each well followed by 100 µl of Proteinase K (20 mg/ml) and 
incubating overnight at 50ºC. The ES buffer was then aspirated and the plugs 
washed at least 5 times with 5 ml of TE buffer. 
 
Restriction digestion of the DNA in the plugs was performed in 96-well tissue 
culture plates. Each well contained 4 µl of 10X restriction enzyme buffer, 36 
µl of DNase/RNase-free water, 1 µl of restriction enzyme and 1 µl of bovine 









 (Cambrex Bio 
Science Rockland Inc) agarose gel together with a Lambda ladder (BIO-RAD) 
and run in 0.5X TBE in a CHEF MAPPER (BIO-RAD). The initial switch 
time was 5.3 s with a final switch time of 34.9 s using a linear ramp at 6 V/cm 
run for 19.5 h. After completion, the gel was stained in  GelRed™ Nucleic 
Acid Gel Stain (Biotium) for 1 h before viewing in a Gel Doc™ 2000 (BIO-
RAD). 
 
The PFGE band patterns were analyzed in Bionumerics (Applied Maths NV, 
Sint-Martens-Latem, Belgium) and all strains with more than 85% similarity 
were considered to belong to the same clone. 
 
MLST 
All MBL-producing isolates were further subjected to MLST (77). This typing 
method is based on sequencing the following seven house-keeping genes in 
the P. aeruginosa chromosome; acsA (acetyl coenzyme A synthetase), aroE 
(ahikimate dehydrogenase), guaA(GMP synthase), mutL (DNA mismatch 
repair protein), nuoD (NADH dehydrogenase I chain C, D), ppsA 
(phosphoenolpyruvate synthase), and trpE (anthralite synthetase component I). 
MLST is able to characterize bacterial types in an unambiguous fashion and 
establish evolutionary relationships between strains better than band based 




The PCR reaction mixture was made up using the QIAGEN Taq PCR Master 
Mix Kit as described above. The cycling conditions for amplification were: 
initial denaturation at 96ºC for 1 min, followed by 30 cycles of denaturation at 
96ºC for 1 min, annealing at 55ºC for 1 min, and elongation at 72ºC for 1 min, 
followed by a final elongation step at 72ºC for 10 min.  
 
Table 3 Primers used for amplification of house-keeping genes for P. 
aeruginosa MLST. 





aroE aroE-F TGGGGCTATGACTGGAAACC 
aroE-R TAACCCGGTTTTGTGATTCCTACA 
guaA guaA-F CGGCCTCGACGTGTGGATGA 
guaA-R GAACGCCTGGCTGGTCTTGTGGTA 
mutL mutL-F CCAGATCGCCGCCGGTGAGGTG 
mutL-R CAGGGTGCCATAGAGGAAGTC 
nuoD nuoD-F ACCGCCACCCGTACTG 
nuoD-R TCTCGCCCATCTTGACCA 
ppsA ppsA-F GGT CGC TCG GTC AAG GTA GTG G 
ppsA-R GGGTTCTCTTCTTCCGGCTCGTAG 





The amplified PCR products were cleaned up as described previously and sent 
to a commercial company for sequencing (AITbiotech, Singapore). 
 
Table 4 Primers used for sequencing of house-keeping genes for P. aeruginosa 
MLST. 





aroE aroE-F ATGTCACCGTGCCGTTCAAG 
aroE-R TGAAGGCAGTCGGTTCCTTG 
guaA guaA-F AGGTCGGTTCCTCCAAGGTC 
guaA-R GACGTTGTGGTGCGACTTGA 
mutL mutL-F AGAAGACCGAGTTCGACCAT 
mutL-R GGTGCCATAGAGGAAGTCAT 
nuoD nuoD-F ACGGCGAGAACGAGGACTAC 
nuoD-R TGGCGGTCGGTGAAGGTGAA 
ppsA ppsA-F GGTGACGACGGCAAGCTGTA 
ppsA-R GTATCGCCTTCGGCACAGGA 
trpE trpE-F TTCAACTTCGGCGACTTCCA 
trpE-R GGTGTCCATGTTGCCGTTCC 
 
MLST profiles were obtained by submitting the sequences to the P. 
aeruginosa MLST Database (http://pubmlst.org/paeruginosa/). MLST profiles 
were submitted to eBURST V3 (http://eburst.mlst.net/) on 19 January 2013. 
Isolates sharing six out of seven alleles were assigned to the same BURST 
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group and were considered to belong to the same clonal complex descended 
from a common founder genotype. Representative MBL-producing P. 
aeruginosa from the 2000 survey were also subjected to PFGE and MLST. 
 
Results 
One hundred and twenty-three isolates of 2,552 non-duplicate P. aeruginosa 
isolated in 2008 were imipenem-resistant. Nine isolates were positive for 
carbapenemase by the modified Hodge test, MBL production by imipenem-
EDTA disk diffusion, and multiplex PCR for MBL genes. Seven 
representatives from the two major clones in 2000 that carried blaIMP-1 or its 
variant blaIMP-1v, and the solitary isolate with blaIMP-7 were also re-investigated 
for comparison. The PFGE, MBL gene sequence and MLST results are 
summarized in Figure 1. The eBURST anaysis showed that ST233 is the 
founder of a small clonal complex including ST742 and ST743 (CC233 or 
BURST Group 29). ST235 is a founder of a large clonal complex (CC235 or 
BURST Group 3)  that includes ST745 and ST654 is a founder of a small 




Figure 1 Dendrogram of PFGE patterns of P. aeruginosa isolates with MBL 
genes. The source of the isolate is indicated by the 2 letter prefix of the 
specimen number: DM; miscellaneous (including wounds), DU; urine, DR; 
respiratory; DB; blood. Reprinted with permission. Copyright © American 







































































































































































































































In our previous study, 21 of 2,094 (1.0%) of all non-duplicate P. aeruginosa 
isolates in our hospital had MBL genes (59). With the exception of 1 isolate 
with blaIMP-7, all other isolates had blaIMP-1 and belonged to 1 of 2 PFGE 
clones. Isolates belonging to clone A had sequences identical to that of the 
original blaIMP-1 first reported in Japan. Four representatives of clone A 
isolated from our hospital in 2000 had ST964 by MLST. Isolates belonging to 
clone B isolated in 2000 had sequences for variant blaIMP-1 (blaIMP-1v) with 4 
silent mutations. Three representatives of this clone from 2000 had ST233 and 
one had ST742 by MLST. All four representatives of clone B belong to the 
same BURST group which was different from that of clone A. 
 
In contrast, in the 2008 survey, 9 of 2,552 (0.35%) non-duplicate P. 
aeruginosa had MBL genes. Unlike the earlier study, there were no large 
clonal outbreaks. Two isolates with blaIMP-1v had similar PFGE patterns and 
belonged to the same BURST group as representative isolates from clone B in 
2000. 
 
Two isolates from 2008 with blaIMP-7 had similar PFGE patterns and shared 
the same BURST group. The rest of the isolates from 2008 had distinct PFGE 
patterns.  
 
There was a greater diversity of MBL genes compared to the 2000 survey. In 
particular, this is the first time that blaVIM-2, and blaVIM-6, have been found in 
P. aeruginosa in Singapore.  blaIMP-26 is a novel MBL gene that differs from 
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blaIMP-4 at position 145 (G to T). The translated amino acid sequence differs 
from IMP-4 at residue 49 (Phenylalanine for Valine). This sequence has been 
previously deposited in the GenBank database as IMP-4 in an A. calcoaceticus 
from Malaysia (accession number ABC24668.1). 
 
Three of the isolates in this study (separately containing blaVIM-2, blaIMP-1, and 
blaIMP-7) belonged to ST235. This sequence type has been described in a VIM-
producing P. aeruginosa isolate in Belgrade and is the founder of an 
international clonal complex of isolates bearing MBL genes found in several 
countries in Europe (78). Recently, an increasing prevalence of IMP-1-
producing P. aeruginosa has been found in Hiroshima, Japan. This was due 
entirely to the clonal expansion of only two lineages, ST235 (BURST group 3) 
and ST357 (BURST group 108) (79). This is similar to the situation that 
existed in Singapore in 2000 where only two lineages (BURST groups 29 and 
44) accounted for the majority of MBL-producing P. aeruginosa (59).  
 
It is noteworthy that the original fear that a clone of MBL-producing P. 
aeruginosa would become established in Singapore has not been realized. The 
BURST group 29 and 44 lineages from 2000 are represented by only 1-2 
isolates in 2008. The 2 P. aeruginosa with blaIMP-7 in 2008 are unrelated to the 
solitary isolate with blaIMP-7 in 2000.  It has been suggested that P. aeruginosa 
displays an epidemic population structure with a limited number of clones 
emerging from a large number of unrelated genotypes (80). Although we did 
not correlate our study with hospital infection control measures, the Japanese 
data and our own seems to suggest that controlling the prevalence of MBL-
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producing P. aeruginosa may be achieved by preventing the transmission of 
specific epidemic clones.  
 
While it is reassuring to note that the prevalence of MBLs in carbapenem-
resistant P. aeruginosa has not increased, the increased diversity of MBL 
genes represents a new cause for concern. Although clones of MBL-producing 
P. aeruginosa have not become established, it seems likely, given the variation 
of MBL genes and MLST types in this study, that MBL-producing P. 





Chapter 3 Acquired Carbapenemases in Acb 
 
Introduction 
The Acb comprises A. calcoaceticus, A. baumannii, A. pittii and A. 
nosocomialis. A. calcoaceticus is rarely found in clinical specimens whereas 
A. baumannii is a well-established pathogen. The significance of A. pittii and 
A. nosocomialis is largely unknown because Acb are not routinely identified to 
species level in the clinical laboratory.  
 
The increasing prevalence of multidrug-resistant Acb, in particular 
carbapenem-resistant A. baumannii in several Asia countries is alarming.  We 
also noted this trend in one preliminary study in Singapore (62). The current 
study was carried out to determine the prevalence, distribution of specimen 
sources, and antimicrobial susceptibility of Acb in Singapore.  
 
Materials and methods 
 
Bacterial isolates 
A total of 193 serial unselected non-replicate Acb clinical isolates were 
collected from patients with suspected clinical infection in 6 hospitals 
[Alexandra Hospital (Hospital A), KK Women’s and Children’s Hospital (K), 
National University Hospital (N), Changi General Hospital (C), Singapore 
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General Hospital (S), and Tan Tock Seng Hospital (T)] in Singapore over a 1-
month period in 2006.  
 
Identification of A. baumannii by one tube multiplex PCR 
Identification of A. baumannii was carried out by a one tube multiplex PCR 
targeting an internal 208 bp fragment from the intergenic spacer (ITS) region 
of A. baumannii and a highly conserved 425 bp region of the recA gene of 
Acinetobacter spp. (81).  Clinical isolates of A. baumannii and Acinetobacter 
lwoffi were used as controls. 
 
Table 5 Primers used in one tube multiplex PCR for identification of A. 
baumannii. 
Target Name Primer (5’-3’) 
ITS P-Ab-ITSF CATTATCACGGTAATTAGTG 
P-Ab-ITSB AGAGCACTGTGCACTTAAG 
recA P-rA1 CCTGAATCTTCTGGTAAAAC 
P-rA2 GTTTCTGGGCTGCCAAACATTAC 
 
Multiplex PCR was carried as described in Chapter 2. The cycling conditions 
were: initial denaturation at 95ºC for 15 min, followed by 30 cycles of 
denaturation at 94ºC for 30 s, annealing at 55ºC for 30 s, and elongation at 






Identification of Acb other than A. baumanii by ITS sequencing 
ITS sequencing was used for identification of other members of the Acb (82). 
The primers 1512F 5’-GTCGTAACAAGGTAGCCGTA-3’ and 6R 5’-
GGGTTYCCCCRTTCRGAAAT-3’ were used to amplify a DNA fragment 
spanning from the 16S rRNA gene region to the small fragment of the 23S 
rRNA gene region. . The cycling conditions were: initial denaturation at 94ºC 
for 2 min, followed by 35 cycles of denaturation at 94ºC for 1 min, annealing 
at 62ºC for 1 min, and elongation at 72ºC for 1 min, followed by a final 
elongation step at 72ºC for 7 min. The PCR products were cleaned up and 
sequenced as described in Chapter 2 using the same primers used for 
amplification. The obtained sequences were trimmed at the 5’ and 3’ ends to 
yield the ITS sequence starting with ACGAAAGATT and ending with 
GGGGTTGTAT before querying the GenBank database to identify the 
species. 
 
Confirmation of Acb species by amplified fragment length polymorphism 
(AFLP™) analysis 
Selective amplification of restriction fragments using AFLP™ analysis was 
also used for confirmatory identification where necessary (83).  The 
methodology of AFLP™ is given below. 
 
Antimicrobial susceptibility testing 
Minimal inhibitory concentrations (MICs) of sulbactam-ampicillin (SAM), 
piperacillin-tazobactam (TZP), ceftazidime (CAZ), cefepime (FEP), imipenem 
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(IPM), meropenem (MEM), amikacin (AMK), gentamicin (GEN), 
ciprofloxacin (CIP), polymixin B (POL), and tigecycline (TGC) were carried 
out by microbroth dilution using custom Sensititre plates (TREK Diagnostic 
Systems, LTD, East Grinstead, United Kingdom). E. coli ATCC 25922 and P. 
aeruginosa ATCC 27853 were used for quality control of plates upon delivery 
and once a week during testing. Antimicrobial susceptibilities were interpreted 
in accordance with the guidelines of the Clinical Laboratory Standards 
Institute (84), except for tigecycline where the manufacturer’s breakpoints for 
Enterobacteriaceae were used. 
 
PCR for OXA, MBL genes, and insertion sequences 
We sought blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, blaOXA-58-like, and blaOXA-143 
carbapenemase genes by multiplex PCR (85, 86). The cycling conditions 
were: initial denaturation at 95ºC for 15 min, followed by 30 cycles of 
denaturation at 94ºC for 25 s, annealing at 52ºC for 40 s, and elongation at 
72ºC for 50 s, followed by a final elongation step at 72ºC for 6 min. 
 
Table 6 Primers used in multiplex PCR for OXA genes. 









blaOXA-24- OXA-24-F GGTTAGTTGGCCCCCTTAAA 
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blaOXA-143 OXA-143-F TGGCACTTTCAGCAGTTCCT 
OXA-143-R TAATCTTGAGGGGGCCAACC 
 
The presence of insertion sequences preceding the blaOXA genes in 
carbapenem-resistant (meropenem or imipenem MIC ≥ 8 mg/L) isolates was 
determined using the forward primers ISAba1B, ISAba2A, ISAba3C, and 
ISAba4B in combination with reverse primers for blaOXA genes (87, 88).  
Table 7 Forward primers of insertion sequences. 
Gene Name Primer (5’-3’) 
ISAba1 ISAba1B CATGTAAACCAATGCTCACC 
ISAba2 ISAba2A AATCCGAGATAGAGCGGTTC 
ISAba3 ISAba3C AGCAATATCTCGTATACCGC 
ISAba4 ISAba4B ACTCTCATATTTTTTCTTGG 
  
MBL genes were sought using the multiplex method previously described in 
Chapter 2 (74).  
 
Random amplified polymorphic DNA (RAPD) analysis 
Ninety-three isolates with an imipenem MIC ≥ 8 µg/ml were subjected to 
RAPD analysis (89). For RAPD using the M13 primer (5’-
GAGGGTGGCGGTTCT-3’), the cycling conditions were: initial denaturation 
at 95ºC for 15 min, followed by 35 cycles of denaturation at 94ºC for 20 s, 
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annealing at 50ºC for 1 min, and elongation at 72ºC for 20 s, followed by a 
final elongation step at 72ºC for 5 min. For RAPD using the DAF4 primer (5’-
CGGCAGCGCC-3’), the cycling conditions were 95°C for 15 minutes, 
followed by 45 cycles of denaturation at 94°C for 40 seconds, annealing at 
45°C for 40 s, and elongation at 72°C for 40 s, followed by a final extension at 
72°C for 5 minutes.  The PCR products were run in 2% agarose gels in 0.5X 
TBE at 90V.  The stained gel images were uploaded onto a computer and the 
band patterns analyzed in Bionumerics (Applied Maths NV). 
 
AFLP™ 
AFLP™ was used to type ten isolates of carbapenem-resistant A. baumannii 
from the present study, and seven archived isolates from Hospital S. The latter 
included 5 carbapenem-resistant A. baumannii characterized from a previous 
study (61), a carbapenem-susceptible A. baumannii (DU53770), and the oldest 
carbapenem-resistant A. baumannii in the archive (DB24815 isolated in 1993 
from a patient on the Burns unit).  
 
DNA isolation was performed according to the method by Boom et al (90). A 
fresh bacterial culture was prepared on Mueller Hinton agar and incubated 
overnight at 30ºC. A grain-sized amount of culture was suspended in 100 µl of 
TE buffer in an Eppendorf tube. To this was added 1 ml of Lysis Buffer 
(Appendix 2) and the tube tilted until the fluid cleared. This was then mixed 
for 1 min with 40 µl of Celite (Janssen Chemica, Beerse, Belgium). The tubes 
were centrifuged for 20 s at 14,000 rpm. The supernatant was discarded 
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carefully using a vessel containing 5 N NaOH to avoid the formation of 
cyanide gas. The pellet was washed 2X with 900 µl Wash Buffer (Appendix 
2), remembering to collect the supernatant in 5 N NaOH, 2X with 900 µl 70% 
non-denatured ethanol, and 1X with 900 µl acetone. The pellet was carefully 
homogenized at each step by stirring with the pipette tip. Each centrifugation 
step was performed at 14,000 rpm for 20 s. After the last step, as much of the 
fluid was discarded as possible and the pellet dried for 10 min in a heating 
block at 56ºC until the acetone smell was no longer present. The pellet was 
rehydrated and homogenized thoroughly with 100 µl of TE buffer and the 
tubes placed in a shaking water bath at 56ºC. After this, the tubes were 
centrifuged for 5 min at 14,000 rpm and the supernatant transferred to a clean 
Eppendorf tube. This was incubated at 37ºC for 15 min with 25 µl RNAse 
(0.25 mg/ml). The DNA concentration was measured and diluted down to 10 
ng/µl with milli-Q water (EMD Millipore, Billerica, MA, USA). 
 
AFLP™ was performed as described by Nemec et al (91) using adapters 













Restriction digestion of 10-50 ng template DNA with 1U EcoRI  (Amersham 
Pharmacia Biotech, Roosendaal, The Netherlands) and 1U MseI (New 
England Biolabs) was performed simultaneously with adapter ligation at 37ºC 
for 3 h in a 10 µl volume containing 4U T4 ligase (Amersham Pharmacia 
Biotech), 1X T4 DNA ligase buffer, 500 ng BSA, 50 mM NaCl, 2 pmol EcoRI 
adapters and 20 pmol MseI adapters. After incubation, the mixture was diluted 
to a final volume of 200 µl with 10 mM Tris-HCl, 0.1 mM EDTA (pH 8.0). 
 
PCR was performed in a final reaction volume of 10 µl containing 5 µl of the 
digestion/ligation mixture, 20 ng FAM-labelled  EcoRI+A primer (FAM-
GACTGCGTACCAATT Ca-3’ ; where a is a selective A base), 60 ng MseI+C 
primer (5’-GATGAGTCCTGAGTAAc-3’ ; where c is a selective C base), 1X 
Taq polymerase buffer, 1.5 mM MgCl2, 0.2 mM of each dNTP and 1 U 
Goldstar Taq DNA polymerase (Eurogentec, Maastricht, The Netherlands). 
The cycling conditions were 72°C for 2 min and 94°C for 2 min; 13 cycles of 
94°C for 30 s, 65°C for 30 s with the annealing temperature lowered by 0.7°C 
for each subsequent cycle, 72°C for 60 s; 23 cycles of 94°C for 30 s, 56°C for 
30 s and 72°C for 60 s; followed by a final elongation step of 72°C for 10 min.   
 
The PCR products were mixed with 3 µl formamide containing 0.5% dextran 
blue, heated at 95°C for 5 min and cooled on ice. Samples of 3 µl were run in 
POP-4® Polymer (Applied Biosystems) and the amplicons were separated 
with an ALF express system (Amersham Pharmacia Biotech). The profiles 
with fragments of 50 to 500 bp were investigated by cluster analysis using 
Bionumerics 5.1 software (Applied Maths) with Pearson’s coefficient for 
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similarity and UPGMA for grouping. Isolates were compared to each other 
and to a library of >2000 reference strains of all Acinetobacter spp. including 
taxonomically and epidemiologically defined strains. Isolates were identified 




Isolates representing significant clones were subjected to MLST using the 
Institut Pasteur scheme 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html). This 
is based on sequencing the following seven house-keeping genes in the A. 
baumannii chromosome; cpn60 (60-kDa chaperonin), fusA (elongation factor 
EF-G), gltA (citrate synthase), pyrG (CTP synthase), recA (homologous 
recombination factor), rplB (50S ribosomal protein L2), and rpoB (RNA 
polymerase subumit B). 
 
Table 8 Primers used for amplification of house-keeping genes for A. 
baumannii MLST. 





fusA fusA:F:fusA7 ATCGGTATTTCTGCKCACATYGAT 
fusA:R:fusA8 CCAACATACKYTGWACACCTTTGTT 




pyrG pyrG:F:pyrG7 GGTGTTGTTTCATCACTAGGWAAAGG 
pyrG:R:pyrG8 ATAAATGGTAAAGAYTCGATRTCACCMA 
recA recA:F:RA1 CCTGAATCTTCYGGTAAAAC 
recA:R:RA2 GTTTCTGGGCTGCCAAACATTAC 
rplB rplB:F:rplB7 GTAGAGCGTATTGAATACGATCCTAACC 
rplB:R:rplB8 CACCACCACCRT GYGGGTGATC 
rpoB rpoB:F:Vic4 GGCGAAATGGC(AGT)GA(AG)AACCA 
rpoB:R:Vic6 GA(AG)TC(CT)TCGAAGTTGTAACC 
 
The cycling conditions were: initial denaturation at 95°C for 2 min, followed 
by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 50°C for 30 
s, and elongation at 72°C for 30 s, followed by a final extension at 72°C for 5 
min. Sequencing was performed in both directions with the same primers used 
for amplification. MLST profiles were submitted to eBURST V3 
(http://eburst.mlst.net/) on 19 January 2013. Isolates sharing six out of seven 
alleles were assigned to the same BURST group and were considered to 




Identification of Acb by 1 tube multiplex PCR, ITS sequencing and AFLP™. 
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Of the 193 isolates, 152 were identified to A. baumannii (78.7%) by multiplex 
PCR, and 18 to A. pittii (9.3%), and 23 to A. nosocomialis (11.9%) by ITS 
sequencing. Both AFLP™ and ITS sequencing were in agreement for the non-
baumannii strains. The distribution of isolates according to the type of 
specimen is shown in Table 9. It is noteworthy that most (63.2% A. 
baumannii, 55.6% A. pittii, 60.9% A. nosocomialis) were recovered from 
respiratory and wound specimens and the respective proportions from blood 
for these species were 7.2%, 16.7% and 26.1%. A. baumannii and A. pittii 
were found in similar frequency from urine specimens (25.7% and 27.8%, 
respectively).  
 
Table 9 Distribution of Acb by specimen of 193 clinical isolates from 6 

























































Total 152 18 23 
Strain Origin KLOON
LUH 08397 CZ 1
LUH 08399 CZ 1
LUH 06125 Krakaw, PL        1
LUH 04621 Brno, CZ                1
LUH 04624 Ceske, CZ      1
LUH 08402 CZ 1
LUH 14613 Singapore                
LUH 03787 Prague, CZ              1
LUH 04576 Prague, CZ              1
RUH 2037 Venlo, NL               1
RUH 3239 London, UK              1
RUH 3238 Sheffield, UK           1
RUH 3247 Leuven, BE              1
LUH 04640 Tabor, CZ               1
RUH 0875 Dordrecht, NL           Reference strain EU clone I 1
RUH 0510 Nijmegen, NL            1
RUH 3242 Basildon, UK            1
RUH 3282 Salford, UK             1
LUH 03783 Prague, CZ              1
LUH 14604 Singapore                
LUH 08398 CZ 1
LUH 08400 CZ 1
LUH 08404 CZ 1
LUH 08401 Usti Nad Labem, CZ      1
LUH 04596 Pribram, CZ             1
RUH 0436 Utrecht, NL             1
LUH 04607 Slany, CZ               1
LUH 04620 Plzen, CZ       1
LUH 03782 Prague, CZ              1
LUH 06015 Rome, IT                1
LUH 06017 Rome, IT                1
LUH 05874 Lille, FR               3
LUH 05875 Utrecht, NL             Reference strain EU clone III 3
LUH 06009 Paris, FR               3
LUH 06028 Seville, ES             3
LUH 06035 Madrid, ES              3
LUH 06037 Barcelona, ES           3
LUH 06030 Seville, ES             3
LUH 14608 Singapore                
LUH 14609 Singapore                
LUH 14607 Singapore                
LUH 14603 Singapore                
LUH 14037 Singapore                
LUH 14039 Singapore                
LUH 14612 Singapore                
LUH 05865 Barcelona, ES           2
LUH 06044 Barcelona, ES           2
RUH 3240 Newcastle, UK 2
LUH 06011 Athene, GR 2
LUH 06034 Madrid, ES              2
LUH 06126 Coimbra, PT   2
RUH 3245 Salisbury, UK           2
LUH 05868 Lille, FR     2
LUH 06024 Seville, ES             2
LUH 06029 Seville, ES             2
LUH 04578 Prague, CZ              2
LUH 04625 Ceske, CZ          2
LUH 03788 Prague, CZ              2
LUH 04623 Jihlava, CZ             2
LUH 04603 Tabor, CZ               2
LUH 04629 Prague, CZ              2
LUH 08405 Prague, CZ              2
RUH 0134 Rotterdam, NL           Reference strain EU clone II 2
RUH 3422 Odense, DK     2
LUH 06021 Krakaw, PL        2
LUH 14031 Singapore                
LUH 14598 Singapore                
LUH 14599 Singapore                
LUH 14601 Singapore                
LUH 14602 Singapore                
LUH 14610 Singapore                
LUH 14611 Singapore                
LUH 14030 Singapore                                                       






































































































































































































































































































































































95908580757065 Strain rigin L
L  08397 Z 1
L  08399 Z 1
L  06125 Kraka , PL 1
L  04621 Brno, Z 1
L  04624 eske, Z 1
L  08402 Z 1
L  14613 Singapore  
L  03787 Prague, Z 1
L  04576 Prague, Z 1
 2037 Venlo, L 1
 3239 London, K 1
 3238 Shef ield, K 1
 3247 Leuven, BE 1
L  04640 Tabor, Z 1
 0875 ordrecht, L eference strain E  clone I 1
 0510 ij egen, L 1
 3242 Basildon, K 1
 3282 Salford, K 1
L  03783 Prague, Z 1
L  14604 Singapore  
L  08398 Z 1
L  08400 Z 1
L  08404 Z 1
L  08401 sti ad Labe , Z 1
L  04596 Pribra , Z 1
 0436 trecht, L 1
L  04607 Slany, Z 1
L  04620 Plzen, Z 1
L  03782 Prague, Z 1
L  06015 o e, IT 1
L  06017 o e, IT 1
L  05874 Lil e, F  3
L  05875 trecht, L eference strain E  clone I 3
L  06009 Paris, F  3
L  06028 Sevil e, ES 3
L  06035 adrid, ES 3
L  06037 Barcelona, ES 3
L  06030 Sevil e, ES 3
L  14608 Singapore  
L  14609 Singapore  
L  14607 Singapore  
L  14603 Singapore  
L  14037 Singapore  
L  14039 Singapore  
L  14612 Singapore  
L  05865 Barcelona, ES 2
L  06044 Barcelona, ES 2
 3240 e castle, K 2
L  06011 Athene,  2
L  06034 adrid, ES 2
L  06126 oi bra, PT 2
 3245 Salisbury, K 2
L  05868 Lil e, F  2
L  06024 Sevil e, ES 2
L  06029 Sevil e, ES 2
L  04578 Prague, Z 2
L  04625 eske, Z 2
L  03788 Prague, Z 2
L  04623 Jihlava, Z 2
L  04603 Tabor, Z 2
L  04629 Prague, Z 2
L  08405 Prague, Z 2
 0134 ot erda , L eference strain E  clone I 2
 3422 dense, K 2
L  06021 Kraka , PL 2
L  14031 Singapore  
L  14598 Singapore  
L  14599 Singapore  
L  14601 Singapore  
L  14602 Singapore  
L  14610 Singapore  
L  14611 Singapore  
L  14030 Singapore  







































































































































































































































































































































































Antimicrobial susceptibility testing 
The antimicrobial resistance profiles of the different species are shown in 
Figure 3. A high proportion of A. baumannii (110 isolates, 72.4%), but also 5 
(27.8% of) A. pittii and 8 (34.8% of) A. nosocomialis were resistant to 
carbapenems. Overall, 150 isolates (77.7%) were multidrug-resistant, defined 
as resistant to 3 or more antimicrobial agents. This comprised 127 of A. 
baumannii isolates (83.6%), 11 of A. pittii isolates (61.1%), and 12 of A. 
nosocomialis isolates (52.2%).  
 
Figure 3 Antimicrobial resistance profile of A. baumannii (black), A. pittii 
(grey), and A. nosocomialis (white). Reprinted with permission. Copyright © 







PCR for OXA, MBL genes, and insertion sequences 
One hundred and sixteen isolates (108 A. baumannii, 8 A. nosocomialis) were 
positive for blaOXA-23-like. Of the isolates that were resistant to imipenem, 
ISAba1 was located upstream of this OXA-gene (ISAba1-blaOXA-23-like) in 70 
A. baumannii and 7 A. nosocomialis. Only 2 imipenem-susceptible A. 
baumannii had blaOXA-23-like. In both cases, there was no IS element upstream 
of the blaOXA-23-like gene. All A. baumannii, and 1 A. nosocomialis were 
positive for the blaOXA-51-like gene. Of the imipenem-resistant A. baumannii, 
ISAba1 was upstream of the OXA-51-like gene in only 12 isolates (ISAba1-
blaOXA-51-like). In only 3 of these was ISAba1-blaOXA-51-like likely to be the 
major contributor to imipenem resistance as the remainder also possessed 
ISAba1-blaOXA-23-like concurrently.  
 
Thirteen isolates were positive for blaOXA-58-like (1 A. baumannii, 4 A. 
nosocomialis, and 8 A. pittii). Among the imipenem-resistant isolates, this 
gene was preceded by ISAba3 (ISAba3-blaOXA-58-like) in 1 A. nosocomialis and 
3 A. pittii isolates. Only 1 imipenem-resistant A. baumannii isolate (positive 
for blaOXA-51-like, and blaOXA-23-like, both lacking ISAba1 upstream) and one 
imipenem-resistant A. pittii (positive for  ISAba3-blaOXA-58-like) had blaIMP-like. 
None of the isolates tested were positive with primers for blaOXA-24-like, blaOXA-
143, ISAba2, or ISAba4. 
 
RAPD analysis 
Two isolates failed to produce patterns with the M13 primer. The RAPD PCR 
patterns using DAF4 and M13 primers were difficult to interpret and 
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discrepant.  Because the DAF4 RAPD PCR patterns were complete and more 
complex, we used them to choose a number of representative strains (for each 































































































































































































































































































































































































































Closest to A. genomosp. 3
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Figure 5 RAPD PCR results using the M13 primer. 
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AFLP™ analysis and MLST 
Final identification of Acb to species by AFLP™ was in agreement with ITS 
sequencing or multiplex PCR identification. None of the included A. pittii and 
A. nosocomialis isolates clustered at 90% or above (Appendix 3). Among the 
A. baumannii isolates, the AFLP™ clustering pattern was more similar to that 
of RAPD PCR with the DAF4 primer than the M13 primer justifying the 
earlier decision to place more reliance on the DAF4 patterns. Three clusters of 
isolates grouped with ≥90% similarity (see Figure 6) indicating a high degree 
of genotypic relatedness.  
 
DR25547 represented an outbreak of blaOXA-64 containing A. baumannii 
isolated from hospital S in the eastern part of Singapore. This was the 
dominant outbreak strain in this hospital in 1996. DM09676 represented a 
cluster of blaOXA-88 containing A. baumannii isolated from hospital S in the 
same year (61).  
 
Comparison of AFLP™ profiles of the isolates to those of the Leiden database 
including strains identified to the European (International) clones I-III showed 
that 2 isolates clustered with clone I isolates at 80%, whereas 7 isolates were 
linked with clone II isolates at 78%. No isolate was found to cluster with clone 
III. All strains that clustered with International clones were resistant to 
imipenem and were positive for blaOXA-23-like with one exception (DU05665). 
 
NUH M100227 (International clone I) was a representative of a cluster of 
isolates from hospitals A and N in the western part of Singapore in 2006. 
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DM18905 represented a cluster of blaOXA-69 containing A. baumannii isolated 
from hospital S in 2001 (61). It also belonged to clone I, but was distinct from 
NUH M100227/06. Both were ST1 belonging to CC1 by MLST. 
 
Of the seven isolates of the Singapore cluster linked with clone II at 78%, 
DM02370, DM02871, DM01800, and DU35210 were all isolated from 
hospital S, and represented a local clone that has persisted in this hospital from 
at least 2001 to 2006. DU35210 contained blaOXA-66 and was part of the 
predominant outbreak type in 2001 (61). DU35210 was identified by MLST to 
ST2, CC2. Of the remaining isolates in clone II, DU05665 (blaOXA-23-like 
negative) was also isolated from hospital S. TTS 6023688355 and NUH 
M96260-1 were isolated from hospitals T and N respectively.  
 
Assignment of isolates by AFLP™ to clones I and II correlated with 
assignment by MLST to ST1 and ST2 respectively. These two STs are the 
founders of the two largest clonal complexes in the total population eBURST 
analysis of A. baumannii (see Figure 7), emphasizing the global spread of 
these two clones which appear to be associated with blaOXA-23-like genes (93). 
 
Six isolates, including the predominant outbreak strains from hospital S in 
1996 that contained blaOXA-64 had AFLP™ profiles that were unrelated to 
International clones I-III. Two isolates from 1996, 1 with blaOXA-64 (DR25547) 
and the other with blaOXA-88 (DM9679), were found to have MLST ST25 and 
novel type ST111 respectively. ST25 has been associated with A. baumannii 
in Greece, Italy and Turkey (94). Interestingly DR25547 (ST25) and DU35210 
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(ST2) in the original manuscript were classified in the same cluster by PFGE 
but the MLST data show that they were in fact unrelated in keeping with the 
difference in blaOXA-51-type genes (61). This illustrates the advantage of 
inferring relationships between strains using objective sequence-based typing 
methods like MLST over subjective band-based ones like PFGE. 
 
Figure 6 Comparison of A. baumannii strains from Singapore with reference 
strains belonging to International clones I, II and III (marked in grey) by 




































































































































































































































Carbapenem resistance is increasing in Acb in Asia. The Chinese Meropenem 
Surveillance Study found that the prevalence of meropenem resistance in 
Acinetobacter spp. increased from 5.4% in 2003 to 39.3% in 2008 (95). Wang 
et al collected 221 imipenem-resistant Acinetobacter spp. from 11 hospitals in 
China from 1999 to 2005. One hundred and eighty-seven isolates were A. 
baumannii, 2 were A. pittii, and 5 were A. nosocomialis. Most isolates were 
associated with ISAba1-blaOXA-23-like, whereas no isolates were positive for 
ISAba1-blaOXA-51-like (96).  
 
Another study from China showed that carbapenem resistance was due to 
spread of clones that possessed ISAba1-blaOXA-23-like (97). These isolates 
belonged to CC22 according to the MLST scheme of Bartual, and were 
closely related to International clone II (98). Carbapenem resistance in A. 
baumannii in nearby Hong Kong was likewise associated with ISAba1-blaOXA-
23-like in one study. However there did not seem to be any relationship to 
International clones based on comparison with the Leiden AFLP™ database 
(99).  
 
Carbapenem-resistant Acinetobacter spp. has also increased in Korea. In a 
survey of over 35 hospitals in Korea, imipenem resistance in Acinetobacter 
spp. rose from 1% in 1997, to 13% in 2003, to 22% in 2007 (100, 101). Kim et 
al collected 190 isolates of Acinetobacter spp. in 2007 from 12 hospitals 
throughout Korea. 92.2% were A. baumannii of which 80% carried blaOXA-23-
like. ISAba1-blaOXA-51-like was detected in 22 of the remaining isolates lacking 
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blaOXA-23-like. Two A. baumannii and 1 A. pittii contained blaVIM-2. Eight A. 
pittii and 1 A. nosocomialis contained blaIMP-1-like (102) . A single MLST clone 
ST22 belonging to CC22 was found to be responsible for the majority of 
imipenem-resistant A. baumannii in Korea (103). The prevalence of MBLs in 
Acinetobacter species may be higher in Korea compared to other countries. In 
one study, 26.5% of imipenem-resistant Acinetobacter spp. isolated from 
2003-2004 in one hospital contained blaIMP-1-like, blaVIM-2-like or blaSIM-1-like 
(104). 
 
The mechanisms underlying carbapenem resistance may be quite different 
even for countries that are geographically quite close. In Taiwan, Lee et al 
collected 208 Acinetobacter species (A. baumannii 88.9%, A. pittii 4.8%, and 
A. nosocomialis  4.3%) from 4 hospitals from January 2001-March 2005. The 
imipenem resistance rates were 38.4% in A. baumannii, 70.0% in A. pittii, and 
44.4% in A. nosocomialis. In A. baumannii, carbapenem resistance was most 
associated with ISAba1-blaOXA-51-like, followed by IS1008-blaOXA-58-like, and 
blaOXA-24-like. However, ISAba1-blaOXA-51-like was also found in carbapenem-
susceptible isolates. blaIMP-1 was present in 2 isolates that also had ISAba-
blaOXA-58-like. Surprisingly, unlike the situation in China and Korea, no blaOXA-
23-like were found. Carbapenem resistance in A. pittii and A. nosocomialis were 
associated with ISAba3-blaOXA-58-like, though a few isolates had MBLs like 
blaIMP-1 and blaIMP-8 (105). These results were largely confirmed in a small 
study of multidrug-resistant Acinetobacter species in another hospital in 
Taiwan. A. baumannii comprised 70.7% of isolates, and A. nosocomialis and 
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A. pittii comprised 26.7%, and 2.7% respectively. Most (88%) carbapenem-
resistant A. baumannii were associated with ISAba1-blaOXA-51-like (106).  
 
Alone among the Northeast Asian countries, Japan does not seem to have a 
major problem with carbapenem-resistant Acinetobacter spp. In a large 
multicenter survey of 100 hospitals in 2006, only 2.6% of 874 Acinetobacter 
spp. were resistant to imipenem (107). The reason for this discrepancy is 
unclear, there is a need to compare policies and perform molecular 
epidemiology studies among Asian countries to get more insight into these 
differences. 
 
Surveillance of Acb in Southeast Asia has been less well documented using 
modern laboratory techniques. Multinational surveillance studies of the Asia-
Pacific region exist but inevitably suffer from relatively small numbers that 
may not be representative compared to single country studies (108).  
 
A survey of Acb in Singapore has previously been published based on isolates 
collected in 1996 and 2001 (61). However that study was confined to 
carbapenem-resistant isolates from one hospital only. Carbapenem resistance 
in A. baumannii was associated with blaOXA-23, whereas carbapenem resistance 
in A. pittii and A. nosocomialis was associated with blaOXA-58 and blaIMP-4. At 
the time we did not test for the presence of insertion sequences preceding 




In the present study, almost 80% of Acb clinical isolates in Singapore were A. 
baumannii of which the majority were resistant to multiple antimicrobials. The 
majority of carbapenem-resistant A. baumannii appear to be associated with 
ISAba1-blaOXA-23-like. As in Korea and China, this seems related to the spread 
of International clones with outbreak potential. In hospital S, where archived 
isolates were available for study, International clones were only found from 
outbreak strains from 2001 and 2006 and were not represented among the 
outbreak strains from 1996. There seems to be a discrepancy in the blaOXA 
gene composition between the non-A. baumannii species. blaOXA-23-like was 
found in A. nosocomialis whereas blaOXA-58-like was predominantly in A. pittii.  
 
Turton et al first suggested that ISAba1 located upstream of blaOXA51-like may 
contribute to carbapenem resistance in A. baumannii by acting as a promoter 
(109). This appears to be the situation in Taiwan but does not seem to be a 
major contributor to carbapenem resistance in A. baumannii in Singapore. 
Only 3 isolates of imipenem-resistant A. baumannii had ISAba1-blaOXA-51-like. 
These isolates still possessed blaOXA-23-like though this was not preceded by 
ISAba1. One carbapenem-resistant A. nosocomialis had blaOXA-51-like that was 
not preceded by ISAba1. Lee et al has recently described a blaOXA-51-like gene 
in A. nosocomialis (110). This is thought to have been acquired via a plasmid. 
It has been previously suggested that the presence of blaOXA-51-like genes can 
serve to identify A. baumannii (111). The presence of blaOXA-51-like in A. 
nosocomialis in this and the Taiwanese study (110) suggests that this may not 




Only a few studies have defined the species distribution of Acb in clinical 
specimens (83). Consequently, most attention has been focused on A. 
baumannii. However, recently there has been increased appreciation of the 
clinical significance of other species in the Acb species complex. In our study, 
the relative prevalence of A. nosocomialis seems to be greater than that 
reported in other studies. In Hong Kong, A. pittii was more common than A. 
baumannii in blood cultures in 1997-1998 (112). In an Irish study, clinical 
isolates of A. pittii exceeded that of A. baumannii by a factor of 1.8. 
Carbapenem resistance in A. pittii (22%) also exceeded that of A. baumannii 
(4%) (113). In the Czech Republic, A. nosocomialis made up only 5.4% of 
isolates whereas A. baumannii (mostly clone II but also clone I) and A. pittii 
made up 73.5% and 20.4% respectively (114). A. pittii and A. nosocomialis 
isolates were susceptible to most antimicrobials tested including the 
carbapenems. Further, in an 8-year survey in a University hospital in the 
Netherlands, A. pittii (40.3% of Acb isolates) was second to A. baumannii 
(55.8%) whereas A. nosocomialis (3.9%) was much less common (83). The 
prevalence of multidrug-resistance in A. pittii ranged from 0% to 22% over the 
course of the study and no carbapenem-resistant isolates were detected. 
 
In conclusion, A. baumannii was the predominant species within the Acb in 
clinical specimens in Singapore. Resistance was largely associated with 
ISAba1-blaOXA-23-like and the strains that carried it belonged to the International 
clones which are notorious for their potential to spread. This situation is 
similar to that in China (97) and Korea (103). The relatively high rates of 
occurrence of A. nosocomialis and A. pittii, their presence in blood-stream 
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infections, and the multidrug and carbapenem resistance in these species 





Chapter 4 Acquired Carbapenemases in Enterobacteriaceae 
 
Introduction 
In 1994, Osano et al described a plasmid-borne MBL gene blaIMP-1 in S. 
marcescens in Japan (33). A blaIMP-1-positive K. pneumoniae (DB44384) was 
isolated in Singapore two years later (58). This was the first time a plasmid-
borne carbapenemase had been found in any Enterobacteriaceae outside 
Japan. Since then, the Department of Pathology, Singapore General Hospital 
has actively looked out for Enterobactericeae with reduced susceptibility to 
carbapenems. In this manuscript, we describe our experience to date. 
DB44384 has been partially described before (115) and is included here, 
together with new typing and plasmid data for completeness. 
 
Materials and methods 
Isolates 
All non-duplicate Enterobacteriaceae isolated from patient specimens 
received at the Department of Pathology, Singapore General Hospital that had 
reduced susceptibility (>1 µg/ml) to imipenem, or meropenem by Etest® 
(bioMérieux, Marcy l’Etoile, France) were archived for further testing. The 
identification of the isolates was confirmed by Vitek 2 (bioMérieux) or 
MALDI-TOF (Bruker, Bremen, Germany).  Isolates were collected from 
October 1996 to May 2012. 
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Modified Hodge test 
The isolates were tested by modified Hodge test (116).  The methodology was 
as described in Chapter 2 except that 10 µg meropenem and ertapenem disks 
were used instead of imipenem. 
 
Rosco KPC + MBL Confirm ID Test 
Isolates that were modified Hodge test positive were tested with the KPC + 
MBL Confirm ID test (Rosco Diagnostica, Taastrup, Denmark). This is a 
commercial adaptation of the Imipenem-EDTA disk diffusion test described in 
Chapter 2. The test organism is inoculated onto a Mueller Hinton agar plate as 
previously described. One tablet each of the following is then applied to the 
inoculated agar; meropenem 10 µg, meropenem + dipicolinic acid (DP), 
meropenem + boronic acid (BO) and meropenem + cloxacillin (CX). After 
incubation overnight at 35ºC, the zones of inhibition around the tablets are 
measured. The meropenem + DP will show an increase in the inhibition zone 
diameter compared with the meropenem-only disk of ≥ 5 mm in the presence 
of a MBL. On the other hand the meropenem + BO will show an increase in 
the inhibition zone diameter compared with the meropenem-only disk of ≥ 5 
mm in the presence of a KPC carbapenemase. 
 
PCR for β-lactamase genes 
Screening for β-lactamase genes associated with the carbapenemase-producer 
phenotype was performed by multiplex PCR to blaOXA-48-type, blaKPC, and MBL 
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genes (117). The primers for blaIMP, blaVIM, blaSPM, blaGIM, and blaSIM genes, 
were as previously described in Chapter 2. New primers are listed in the Table 
below. The primers were split between 3 multiplex PCRs performed 
separately. The first multiplex comprised blaIMP, blaVIM, and blaSPM, the 
second comprised blaNDM, blaKPC, and  blaBIC, and the third comprised blaAIM, 
blaGIM, blaSIM, and blaDIM. PCR was carried out in a reaction volume of 50 µl 
with the QIAGEN multiplex PCR Kit (QIAGEN). 
 
Table 10 Primers used in multiplex PCR for carbapenemase genes. 
Gene Name Primer (5’-3’) 
blaAIM AIM-F CTGAAGGTGTACGAAACAC 
AIM-R GTTCGGCCACCTCGAATTG 
bla OXA-48 OXA-F GCGTGGTTAAGGATGAACAC 
OXA-R CATCAAGTTCAACCCAACCG 
blaBIC BIC-F TATGCAGCTCCTTTAAGGGC 
BIC-R TCATTGGCGGTGCCGTACAC 
blaNDM NDM-F GGTTTGGCGATCTGGTTTTC 
NDM-R CGGAATGGCTCATCACGATC 
blaDIM DIM-F GCTTGTCTTCGCTTGCTAACG 
DIM-R CGTTCGGCTGGATTGATTTG 





The cycling conditions were: initial denaturation at 95°C for 15 min, followed 
by 36 cycles of denaturation at 94°C for 30 s, annealing at 52°C for 40 s, and 
elongation at 72°C for 50 s, followed by a final extension at 72°C for 5 min. 
 
PFGE 
PFGE was performed in 1% agarose gels on total DNA extracted from K. 
pneumoniae, E. coli, and E. cloacae following restriction digestion with SpeI. 
For K. pneumoniae and E. cloacae the initial switch time was 0.5 s with a final 
switch time of 30 s using a linear ramp at 6 V/cm run for 20 h. For E. coli, the 
initial switch time was 5.3 s with a final switch time of 49.9 s using a linear 
ramp at 6 V/cm run for 20 hours. The PFGE band patterns were archived in 
Bionumerics (Applied Maths). However, PFGE pulsotypes and subtypes were 
designated according to Tenover’s criteria (118). A representative of each 
distinct pulsotype was selected for further testing. 
 
MLST 
MLST was performed for K. pneumoniae using the Pasteur Institute protocol 
(119). This typing method is based on sequencing the following 7 house-
keeping genes in the K. pneumoniae chromosome; rpoB (β-subunit of RNA 
polymerase), gapA (glyceraldehyde 3-phosphate dehydrogenase), mdh (malate 
dehydrogenase), pgi (phosphoglucose isomerase), phoE (phosphorine E), infB 




Table 11 Primers used for amplification of house-keeping genes for K. 
pneumoniae MLST. 
Gene Name Primer (5’-3’) 












pgi pgi:F:1R:oF GTTTTCCCAGTCACGACGTTGTA 
GAGAAAAACCTGCCTGTACTGCTGGC 
pgi:R :1F:oR TTGTGAGCGGATAACAATTTC 
CGCGCCACGCTTTATAGCGGTTAAT 















The annealing temperature for all primers was 50ºC. Sequencing was 
performed in both directions with the universal primers; primer oF (5’-
GTTTTCCCAGTCACGACGTTGTA-3’) and primer oR (5’-  
TTGTGAGCGGATAACAATTTC-3’). MLST profiles were submitted to 
eBURST V3 (http://eburst.mlst.net/) on 19 January 2013. Isolates sharing six 
out of seven alleles were assigned to the same BURST group and were 
considered to belong to the same clonal complex descended from a common 
founder genotype. 
 
MLST was performed on E. coli using the University of Cork protocol (120). 
This typing method is based on sequencing the following seven house-keeping 
genes in the E. coli chromosome; adK (adenylate kinase), fumC (fumarate 
hydratase), gyrB (DNA gyrase), icd (isocitrate/isopropylmalate 
dehydrogenase), mdh (malate dehydrogenase), purA (adenylosuccinate 
dehydrogenase), and recA (ATP/GTP binding motif). 
 
Table 12 Primers used for amplification of house-keeping genes for E. coli 
MLST. 
Gene Name Primer (5’-3’) 
adK  adkF ATTCTGCTTGGCGCTCCGGG 
adkR CCGTCAACTTTCGCGTATTT 
fumC fumCF TCACAGGTCGCCAGCGCTTC 
fumCR GTACGCAGCGAAAAAGATTC 




icd icdF ATGGAAAGTAAAGTAGTTGT 
TCCGGCACA 
icdR GGACGCAGCAGGATCTGTT 




purA purAF CGCGCTGATGAAAGAGATGA 
purAR CATACGGTAAGCCACGCAGA 
recA recAF CGCATTCGCTTTACCCTGACC 
recAR TCGTCGAAATCTACGGACCGGA 
 
The cycling conditions were: initial denaturation at 95°C for 2 min, followed 
by 30 cycles of denaturation at 95°C for 1 min, annealing at the appropriate 
temperature for 1 min, and elongation at 72°C for 2 min, followed by a final 
extension at 72°C for 5 min. The annealing temperatures were 54ºC for adk, 
fumC, icd, and purA, 58ºC for recA and 60ºC for gyrB and mdh. Sequencing 
was performed in both directions with the same primers used for 
amplification. MLST profiles were submitted to eBURST V3 
(http://eburst.mlst.net/) on 19 January 2013. Isolates sharing six out of seven 
alleles were assigned to the same BURST group and were considered to 




Sequencing of carbapenemase genes and their flanking regions 
Amplification and sequencing of blaIMP, blaNDM, and blaKPC, and their flanking 
regions was performed using previously published protocols (76, 121-123). 
For the flanking regions, PCR was carried out using an internal primer for the 
carbapenemase gene and the appropriate primer for the flanking region.  
 
Table 13 Primers used for amplification of the flanking regions of blaIMP. 
Gene Name Primer (5’-3’) 
Integron INT-5’CS-f CTTCTAGAAAACCGAGGATGC 
INT-3’CS-r CTCTCTAGATTTTAATGCGGATG 





For the flanking regions of blaIMP, the cycling conditions were 35 cycles of 
denaturation at 94°C for 1 min, annealing at the 55°C for 1 min, and 
elongation at 72°C for 5 min (with an increment of 5 s for each cycle). 
 
Table 14 Primers used for amplification of flanking regions of blaNDM. 
Gene Name Primer (5’-3’) 
ISAba125 ISAba125ext ACACCATTAGAGAAATTTGC 
bleMBL bleo-Rev GGCGATGACAGCATCATCCG 
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For the flanking regions of blaNDM, flanking primers were used together with 
NDM-F and NDM-R. The cycling conditions were 95°C for 15 min, followed 
by 30 cycles of denaturation at 94°C for 30 s, annealing at 52°C for 30 s, and 
elongation at 72°C for 2 min, followed by a final extension at 72°C for 7 min. 
 
Table 15 Primers used for amplification of flanking regions of blaKPC. 











For the flanking regions of blaKPC, the cycling conditions were 95°C for 15 
minutes, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 
58°C for 30 s, and elongation at 72°C for 2.5 min, followed by a final 




Table 16 Primers used for amplification of blaOXA-48, blaOXA-181 and their 
flanking regions. 
Gene Name Primer (5’-3’) 













In-house primers were designed using Primer3 (http://primer3.wi.mit.edu) for 
blaOXA-48 and blaOXA-181 and their flanking regions based on sequences in 
GenBank (accession numbers JN626286.1 and JN205800.1). For amplification 
of the blaOXA-48 and blaOXA-181 genes, the cycling conditions were 95°C for 15 
min, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 44°C 
for 30 s, and elongation at 72°C for 1 min, followed by a final extension at 
72°C for 7 min. 
 
Conjugation  
Conjugation of plasmids was attempted by simple plate mating.  Donor 
(carbapenemase-producing isolates) and recipient (E. coli K12 J53 resistant to 
azide or E. coli K12 J53 resistant to rifampicin) were incubated on Luria-
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Bertani (LB) agar (BD), overnight at 35ºC in air. The following day, 1-3 
colonies were inoculated into 5 ml of LB broth (BD) and incubated overnight 
at 35ºC in air in a Heidolph Promax 1020 shaking incubator (Heidolph 
Instruments GmbH & Co, Schwabach, Germany). After incubation, 500 µl of 
donor and 500 µl of recipient were mixed and 100 µl of the mixture inoculated 
onto LB agar (BD). After overnight incubation in air at 35ºC, all the growth on 
the plate was suspended in 5 ml of normal saline with a swab. The suspension 
was vortexed and 100 µl inoculated onto MacConkey agar (Oxoid Ltd, 
Basingstoke, UK) with added meropenem (Sigma, St. Louis, MO, USA) 1-2 
µg/ml and sodium azide (Sigma) 100 µg/ml or rifampicin (Sigma) 200 µg/ml 
as appropriate. The plates were incubated in air for up to 5 days at 35ºC. The 
plates were inspected daily for E. coli transconjugants and up to 5 suspect 
colonies were subcultured for further testing and archiving. The identity of the 
transconjugants was confirmed by a positive spot indole test and decreased 
susceptibility to a panel of β-lactam antibiotics including carbapenems. DNA 
extraction was performed by boiling a suspension of the transconjugants in 
molecular grade water for 15 min. 
 
Chemical transformation 
Isolates that failed to conjugate underwent chemical transformation. Plasmid 
DNA was extracted from carbapenemase-producing isolates using QIAprep 




 Chemical transformation was performed using TaKaRa E. coli DH5α 
competent cells (TaKaRa, Shiga, Japan), or BL21 (DE3) Competent Cells 
(Stratagene, La Jolla, CA, USA). The competent cells were first thawed on 
ice. Plasmid extract (5-10 µl) was added to 100 µl competent cells in an ice-
cold eppendorf tube and mixed by pipetting. After incubating on ice for 30 
min, the mixture was subjected to heat shock at 42ºC for 45 s before 
quenching on ice for 2 min.  LB broth (900 µl) was added and the entire 
mixture was incubated for 45-60 min at 35ºC in a shaking incubator. The cells 
were pelleted by centrifuging at 5,000 rpm for 5 min and the cells spread onto 
LB agar (BD) containing meropenem (Sigma) 1 µg/ml or ampicillin (Sigma) 
50 µg/ml. 
 
Transformation by electroporation 
For plasmids that failed chemical transformation, electroporation was 
attempted using One Shot® TOP10 Electrocomp™ cells (Life Technologies, 
NY, USA). The cells (40 µl) were thawed on ice before adding to 1-2 µl of 
pre-chilled plasmid extract in a microcentrifuge tube on ice and mixed gently 
without pipetting. The cells were then left on ice for 1 min. The cells were 
then transferred to a chilled cuvette and pulsed in a MicroPulsar 
Electroporator (BIO-RAD). SOC medium (1 ml) was added immediately and 
the cells resuspended with a Pasteur pipette. The cell suspension was 
transferred to a polypropylene tube and incubated at 35ºC for 60 min with 
shaking. After incubation, the cells spread onto LB agar (BD) containing 
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meropenem (Sigma) 1 µg/ml or ampicillin (Sigma) 50 µg/ml. Successful 
transformants were processed the same way as transconjugants. 
 
PCR based plasmid replicon typing 
The PCR based plasmid replicon typing method of Carattoli et al was 
performed on DNA extracts of successful transconjugants and transformants 
using the PBRT kit (DIATHEVA, Fano, Italy) (124). This kit comprises a set 
of 8 multiplex PCRs for the amplification of 25 replicons that represent the 
major plasmid incompatibility groups and replicase genes found in resistance 
plasmids circulating in Enterobaceriaceae. 
 
PCR labelling of DNA probes to carbapenemase genes 
PCR labelling of DNA probes was done using the PCR DIG Probe synthesis 
Kit (Roche Diagnostics GmbH, Mannheim, Germany). The DNA templates 
were extracts from isolates DU9800 (blaIMP-1), DM6277 (blaKPC-2), DS8293 
(blaNDM-1), DB4758 (blaOXA-48). The corresponding primer pairs that had been 
used for multiplex PCR detection of carbapenemase genes (117) were used to 
generate each probe with the exception of blaIMP where we used the primers 





Table 17 Primers used to generate DNA probes to carbapenemase genes. 
Gene Name Primer (5’-3’) 
blaIMP IMP-1ASF TGAGCAAGTTATCTGTATTC 
IMP-1ASR TTAGTTGCTTGGTTTTGATG 
bla KPC-2 KPC-Fm CGTCTAGTTCTGCTGTCTTG 
KPC-Rm CTTGTCATCCTTGTTAGGCG 
blaNDM-1 NDM-F GGTTTGGCGATCTGGTTTTC 
NDM-R CGGAATGGCTCATCACGATC 
blaOXA-48 OXA-F GCGTGGTTAAGGATGAACAC 
OXA-R CATCAAGTTCAACCCAACCG 
 
For each labelled probe, a separate unlabelled probe was made to evaluate 
probe labelling. The cycling conditions were: initial denaturation at 95ºC for 2 
min, followed by 30 cycles of denaturation at 95ºC for 30 s, annealing at 60ºC 
for 30 s, and elongation at 72ºC for 40 s followed by a final elongation step at 
72ºC for 7 min. The probes were evaluated by running the PCR products in a 
2% TBE gel. The labelled PCR products had a higher molecular weight than 
the unlabelled products because of the high density labelling with DIG. 
 
S1 nuclease digestion of plasmids carrying carbapenemase genes 
DNA extracts from successful transconjugants, transformants, and strains that 
were unable to transfer the carbapenemase gene were prepared in agarose 
plugs and digested with 10U of S1 nuclease in 150 µl of buffer using a method 
adapted from that described by Barton et al (125).  The digested products were 
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run in a 1% TBE gel using an initial switch time of 5.3 seconds and a final 
switch time of 34.9 seconds with a linear ramp at 6 V/cm run for 20 hours. 
 
Southern blotting of S1 nuclease digested plasmids carrying carbapenemase 
genes  
The gels were first depurinated in 250 mM HCl with shaking at room 
temperature for 20 min. The DNA in the gels was then denatured by 
submerging in Denaturation Solution (0.5 M NaoOH, 1.5 M NaCl) for 2 X 15 
min at room temperature with gentle shaking. After rinsing with sterile, double 
distilled water, the gels were submerged in Neutralization Solution (0.5 M 
Tris-HCl, pH 7.5; 1.5 M NaCl) for 2 X 15 min at room temperature. The gels 
were then equilibrated for at least 10 min in 20X SSC (3 M NaCl, 300 mM 
sodium citrate, pH 7.0). 
 
The blot transfers were set up in an empty Sub Cell electrophoresis tank (BIO-
RAD) by first placing a piece of Whatman 3MM paper to act as a bridge 
between two separate reservoirs containing 20X SSC. A gel-sized piece of 
Whatman 3MM paper soaked in 20X SSC was placed on top of the bridge and 
the gel was then placed upon this with surface where the gel plugs were 
inserted facing the paper (i.e. the gel is flipped over from its orientation during 
electrophoresis). A gel-sized piece of positively charged GeneScreen Plus
®
 
nylon hybridization transfer membranes (NEN™ Life Science Products, 
Boston, USA) was placed on the DNA containing surface of the gel. A dry 
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gel-sized piece of Whatman 3MM paper was placed on the membrane 
followed by a stack of paper towels, a glass plate and a weight of 
approximately 400 g. The blot was allowed to transfer overnight in 20X SSC. 
 
After DNA transfer, the membranes were placed DNA side facing up on 
Whatman 3MM paper that had been soaked in 2X SSC in a CL-1000 
Ultraviolet Crosslinker (UVP, Upland, CA, USA). The wet membrane was 
exposed to UV light for 3 min and rinsed briefly in sterile, double-distilled 
water before being left to air dry. 
 
DNA hybridization of probes onto Southern blots 
Pre-hybridization and hybridization were performed in sealable plastic boxes 
in a Shake ‘n’ Stack hybridization oven (Thermo Electron Corporation, 
Marietta, OH, USA). The hybridization temperatures were 45ºC for blaIMP, 
52ºC for blaNDM, 46ºC for blaOXA, and 52ºC for blaKPC. The membranes were 
first incubated in pre-warmed pre-hybridization buffer-DIG Easy Hyb (Roche) 
for 30 min. The appropriate labelled probe (2 µl of labelled probe per ml of 
hybridization buffer) was placed in a microcentrifuge tube containing 50 µl of 
water and boiled for 5 min to denature the probe. The denatured probe was 
immediately chilled in ice and added to pre-warmed DIG Easy Hyb (3.5 ml 
per 100 cm
2
 of membrane) and mixed by inversion to form the hybridization 
solution. The pre-hybridization buffer was discarded and immediately 
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replaced with hybridization solution. The blots were incubated overnight at the 
appropriate hybridization temperature. 
 
After hybridization, the membranes were removed from the hybridization 
solution and placed in a plastic tray and washed twice for 5 min each with 
Low Stringency buffer (2X SSC containing 0.1% SDS) at room temperature 
with shaking. The Low Stringency buffer was then replaced and the 
membranes washed twice at the appropriate wash temperature for 15 min each 
with preheated  High Stringency Buffer (0.5X SSC + 0.1% SDS at 65ºC for 
blaIMP, 0.1X SSC + 0.1% SDS at 68ºC for blaNDM, blaOXA, and blaKPC).  
 
Visualizing the hybridization reaction 
The membranes were washed for 2 min at room temperature with shaking in a 
plastic container containing Washing Buffer (0.1 M Maleic acid, 0.15 M 
NaCl; pH 7.5; 0.3% Tween 20). The Washing Buffer was then discarded and 
the membranes incubated in freshly prepared Blocking Solution (Roche) for at 
least 30 min with shaking. The Blocking Solution was then discarded and the 
membranes incubated with Antibody Solution (Roche) containing Anti-
digoxigenin-AP diluted in Blocking Solution for 30 min. The antibody 
solution was discarded and the membranes washed twice for 15 min each with 
Washing Buffer. The membranes were then equilibrated for 3 min in 




Each membrane was covered completely with Color Substrate Solution made 
from NBT/BCIP stock solution (Roche) and incubated overnight in the dark 
without shaking. The colour reaction was stopped by rinsing the membrane for 




Plasmid DNA was extracted from successful transconjugants and 
transformants using QIAprep Spin Miniprep Kits (Qiagen). Extracts of 
plasmids that were of the same size by S1 nuclease digestion were digested 
with 20U of HindIII and PstI overnight and run in 2% agarose gels. Plasmids 




During the study period, we collected 41 isolates of Enterobacteriaciae that 
produced carbapenemases from 40 patients. The majority were K. pneumoniae 
(24 isolates), followed by E. coli (8 isolates), Enteroacter cloacae (7 isolates), 
and Citrobacter spp. All isolates with the exception of 3 were isolated from 
patients in the Singapore General Hospital with the remainder referred from 




The ROSCO KPC + MBL Confirm ID Test correctly predicted the presence of 
MBLs in blaNDM and blaIMP positive isolates. blaKPC-2 positive isolates were 
also accurately predicted. Isolates that were modified Hodge test positive but 
negative for the ROSCO KPC + MBL Confirm ID Test were found to have 
either blaOXA-48 or blaOXA-181. 
 
We succeeded in conjugating or transforming all plasmids bearing 
carbapenemase genes with the exception of those bearing blaIMP in K. 
pneumoniae DM23092, DS6941, and E. cloacae DM9800, blaNDM-1 in K. 
pneumoniae DR40294, and all those with blaOXA-181. The results are 
summarized in Table 18.
 Table 18 Characteristics of carbapenemase-producing Enterobacteriaceae. 
Species Isolate Site Year Nationality Carbapenemase MIC (mg L
-1
) PFGE ST Plasmid 
IMP MEM ETP Inc Size (kb) Type 
K. pneumoniae DB44384 Blood 1996 SIN IMP-1 >32 >32 >32 dg 42 A/C c.a. 160 3 
K. pneumoniae DU32157 Urine 2011 SIN IMP-1 4 4 16 KPN9 147 A/C c.a. 150 3 
K. pneumoniae DR37041 Resp 2010 SIN IMP-1 >32 >32 >32 KPN4 885 A/C c.a. 160 3 
C. freundii DU10513 Urine 2012 SIN IMP-1 4 8 16 nd na A/C c.a. 150 3 
E. cloacae DU31899 Urine 2011 SIN IMP-1 1 1 4 ECL1 na A/C c.a. 190 nt 
E. cloacae DM9800 Wound 2011 SIN IMP-1 2 4 >32 ECL2 na nt c.a. 270 nt 
K. pneumoniae DM23092 Wound 2004 BAN IMP-1 3 3 16 KPN1 11 nt nt nt 
K. pneumoniae DS6941 Stool 2010 SIN IMP-4 >32 >32 >32 KPN6 568 nt c.a. 150 nt 
E. cloacae DM8861 CVP tip 2012 SIN KPC-2 8 4 8 ECL7 na neg c.a. 50 2 
E. coli DM6277 Wound 2012 SIN KPC-2 2 2 8 ECO7 3054 neg c.a. 50 2 
K. pneumoniae DR2160 Resp 2012 SIN KPC-2 16 32 16 KPN13 841 neg c.a. 50 2 
K. pneumoniae DU51131 Urine 2011 SIN KPC-2 >32 8 >32 KPN11 11 neg c.a. 50 2 




 K. pneumoniae DU1301 Urine 2010 SIN NDM-1 >32 >32 >32 KPN2 11 neg c.a. 80 10 
K. pneumoniae DU52392 Urine 2011 SIN NDM-1 8 8 >32 KPN10 11 neg c.a. 80 11 
C. sediakii DM5680-1 Tissue 2012 SIN NDM-1 32 32 32 nd na neg c.a. 90 12 
E. cloacae DM5887-3 Wound 2012 SIN NDM-1 >32 >32 >32 ECL6 na R c.a. 110 13 
K. pneumoniae DU1883 Urine 2011 SIN NDM-1 >32 >32 >32 KPN8 147 neg c.a. 120 14 
K. pneumoniae DM3906 Abdo Fluid 2012 SIN NDM-1 >32 >32 >32 KPN8-1 147 FIIK c.a. 160 nd 
E. coli DS8293 Stool 2010 SIN NDM-1 >32 >32 >32 ECO1 2083 FII c.a. 110 15 
E. coli DU48916 Urine 2011 IND NDM-1 >32 >32 >32 dg 405 A/C c.a. 150 16 
E. cloacae DB6217 Blood 2012 RIN NDM-1 16 >32 >32 ECL5 na A/C c.a. 150 16 
E. cloacae DM16303 Wound 2011 SIN NDM-1 >32 32 >32 ECL4 na neg c.a. 40 4 
K. pneumoniae DU43320 Urine 2010 SIN NDM-1 >32 8 >32 KPN5 273 neg c.a. 40 4 
K. pneumoniae DR2834 Resp 2011 MAL NDM-1 >32 >32 >32 KPN5-1 273 neg c.a. 40 4 
K. pneumoniae DS1731 Stool 2011 SIN NDM-1 >32 >32 >32 KPN5 273 neg c.a. 40 4 
E. coli DS205 Stool 2011 BAN NDM-1 >32 >32 >32 ECO2 648 neg c.a. 40 5 
E. cloacae DM15118 Wound 2011 VIE NDM-1 >32 >32 >32 ECL3 na neg c.a. 60 8 




 E. coli DS1878 Stool 2011 SIN NDM-1 2 4 >32 ECO4 2451 A/C c.a. 370 nd 
K. pneumoniae DS159 Stool 2011 RIN NDM-1 >32 >32 >32 KPN8 nd nd nd nd 
K. pneumoniae DU44951 Urine 2010 VIE NDM-1 >32 >32 >32 KPN7 1 nt c.a. 40 nt 
E. coli DM20217 Abdo fluid 2011 SIN NDM-7 >32 >32 >32 ECO5 205 neg c.a. 40 6 
K. pneumoniae DU7433 Urine 2010 BAN NDM-1 >32 >32 >32 KPN3 14 A/C c.a. 60 7 
K. pneumoniae DR40294 Resp 2011 SIN NDM-1 >32 >32 >32 KPN3-1 14 nt c.a. 280 nt 
K. pneumoniae DB53879 Blood 2011 BAN OXA-181 32 >32 >32 KPN3-1 nd nt c.a. 150 nt 
K. pneumoniae DX1083 Resp 2011 BAN OXA-181 >32 >32 >32 KPN3-1 14 nt c.a. 150 nt 
K. pneumoniae DU54621 Urine 2011 BAN OXA-181 >32 >32 >32 KPN3-1 nd nt c.a. 150 nt 
K. pneumoniae R16-09 Resp 2012 SIN OXA-181 >32 >32 >32 KPN3-1 nd nt c.a. 150 nt 
E. coli DB4758 Blood 2012 SIN OXA-48 >32 32 >32 ECO6 2003 neg c.a. 50 1 
K. pneumoniae DU20470-1 Urine 2012 SIN OXA-48 4 1 8 KPN14 29 neg c.a. 50 1 
dg, degraded; nt, not transferred; nd, not done; na, not applicable; SIN, Singapore; BAN, Bangladesh; VIE, Vietnam;  








Apart from 7 K. pneumoniae (DS159, DU1883 and DM3906 belonging to 
PFGE type KPN8, DR2834, DU43320 and DS1731 belonging to KPN5, 
DU7433 and DR40294 belonging to KPN3), the isolates with blaNDM-1 had 
distinctive PFGE patterns.  The 3 K. pneumoniae with blaKPC-2 had distinct 
PFGE patterns whereas isolates with blaOXA-181 were clonal. Surprisingly, 
blaNDM-1 bearing K. pneumoniae DU7433 and DR40294 had similar PFGE 
patterns to K. pneumoniae with blaOXA-181. These isolates all belonged to ST14 
which may be a common clone in Bangladesh as the majority were isolated 
from patients of Bangladeshi origin. E. coli and E. cloacae with 
carbapenemase genes were not clonal. 
 
Figure 8 PFGE patterns of K. pneumoniae isolates with year of isolation, strain 
number, carbapenemase and MLST sequence type. 
 





























































































































Figure 9 PFGE patterns of E. coli isolates with year of isolation, strain 
number, carbapenemase and MLST sequence type. 
 
 
Figure 10 PFGE patterns of E. cloacae isolates with year of isolation, strain 


























































































The MLST results for K. pneumoniae and E. coli are summarized in Table 18. 
The results correlated well with the PFGE results. For K. pneumoniae, ST11 
and ST14 were the most common whereas the E. coli STs were all different. 
The evolutionary relationship of the isolates from this study to each other 
relative to the whole K. pneumoniae and E. coli MLST databases are shown in 
the figures below.  
 
For K. pneumoniae, ST42 and ST29 are founders of different clonal 
complexes. ST11 and ST14 come from the same clonal complex. ST147 is the 
founder of a clonal complex that includes ST885 and ST273. 
 






























































































































































































































































































































































































































































Sequencing of flanking regions of carbapenemase genes 
For isolates with blaIMP-1, we were only able to obtain integron sequences for 
DU37041 and DB44834. Both were identical with blaIMP-1 followed by an 
aminoglycoside 6’-N-acetyltransferase gene aac(6’)-Ib (aacA4) and a 
dihydrofolate reductase gene dfrA33 (GenBank accession number KC200566). 
blaNDM-1 was always flanked by ISAba125 and a bleomycin resistance protein 
(brp) gene. The flanking regions of blaKPC-2 for DB2244 differed from the 
other blaKPC-2-positive isolates by lacking a truncated blaTEM-1 gene. We were 
unable to obtain flanking sequences for blaOXA-48 and blaOXA-181. 
 










Hybridization of probes to Southern blots of S1 nuclease digested plasmids 
carrying carbapenemase genes  
The hybridization results are given below. The sizes of the plasmids carrying 
carbapenemase genes are given in Table 18. 
 
Figure 14 Hybridization of blaIMP probe to S1 nuclease-digested DNA of IMP-
producing isolates (linearized plasmid indicated by arrows). Each band of the 








Figure 15 Hybridization of blaNDM probe to S1 nuclease-digested DNA of 
NDM-producing isolates (linearized plasmid indicated by arrows). Each band 
of the lambda ladder represents an increment of 48.5 kb over the previous one 




Figure 16 Hybridization of blaKPC probe to S1 nuclease-digested DNA of 
KPC-producing isolates (linearized plasmid indicated by arrows). Each band 





Figure 17 Hybridization of blaOXA-181 probe to S1 nuclease-digested DNA of 
OXA-181-producing isolates (linearized plasmid indicated by arrows). Each 
band of the lambda ladder represents an increment of 48.5 kb over the 
previous one below it. 
 
 
Figure 18 Hybridization of blaOXA-48 probe to S1 nuclease-digested DNA of 
OXA-48-producing isolates (linearized plasmid indicated by arrows). Each 
band of the lambda ladder represents an increment of 48.5 kb over the 






Plasmid fingerprinting and PCR based plasmid replicon typing 
The results are summarized in Table 18. The c.a. 150-160 kb plasmids in K. 
pneumoniae DB44384, DR37041, DU32157 and C. freundii DU10513 with 
blaIMP-1 had the same restriction fingerprint and all belonged to plasmid 
replicon type A/C. The c.a. 40 kb plasmid with blaNDM-1 in K. pneumoniae 
DU43320, DR2834, DS1731 and E. cloacae DM16303 had the same 
restriction fingerprint and was untypable by PCR based plasmid replicon 
typing. The c.a. 150 kb plasmids with blaNDM-1 in E. cloacae DB6217 and E. 
coli DU48916 had the same restriction fingerprint. Both belonged to plasmid 
replicon type A/C. The transferable c.a. 50 kb plasmid with blaOXA-48 in K. 
pneumoniae DU20470-1 and E. coli DB4758 had the same restriction 
fingerprint and both were untypable by PCR based plasmid replicon typing. 
 
Figure 19 HindIII digestions of c.a. 150-160 kb plasmids bearing blaIMP-1. 
Lane 1 pEco_DR37041, Lane 2 pEco_DB44384, Lane 3 pEco_DU10513, 
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Figure 20 PstI digestions of c.a. 150-160 kb plasmids bearing blaIMP-1. Lane 1 





Figure 21 HindIII digestions of c.a. 40 kb plasmids bearing blaNDM. Lane 1 
pEco_DU43320, Lane 2 pEco_DR2834, Lane 3 pEco_DS1731, Lane 4 
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Figure 22 PstI digestions of c.a. 40 kb plasmids bearing blaNDM. Lane 1 
pEco_DU43320, Lane 2 pEco_DR2834, Lane 3 pEco_DS1731, Lane 4 




Figure 23 HindIII digestions of c.a. 60-80 kb plasmids bearing blaNDM. Lane 1 
pEco_DU7433, Lane 2 pEco_DU15118, Lane 3 pEco_DS474, Lane 4 
pEco_DM10361 (not part of this study), Lane 5 pEco_DU1301, Lane 6 
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Figure 24 PstI digestions of c.a. 60-80 kb plasmids bearing blaNDM. Lane 1 
pEco_DU7433, Lane 2 pEco_DU15118, Lane 3 pEco_DS474, Lane 4 
pEco_DM10361 (not part of this study), Lane 5 pEco_DU1301, Lane 6 




Figure 25 HindIII digestions of c.a. 110-150 kb plasmids bearing blaNDM. Lane 
1 pEco_DU5887-3, Lane 2 pEco_DU1883, Lane 3 pEco_DS8293, Lane 4 
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Figure 26 PstI digestions of c.a. 110-150 kb plasmids bearing blaNDM. Lane 1 
pEco_DU5887-3, Lane 2 pEco_DU1883, Lane 3 pEco_DS8293, Lane 4 




Figure 27 HindIII digestions of plasmids bearing blaOXA-48 and blaKPC-2. Lane 
1 pEco_DU20470-1, Lane 2 pEco_DB4758, Lane 3 pEco_DU51131, Lane 4 
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Figure 28 PstI digestions of plasmids bearing blaOXA-48 and blaKPC-2. Lane 1 
pEco_DU20470-1, Lane 2 pEco_DB4758, Lane 3 pEco_DU51131, Lane 4 


















There were 8 isolates with blaIMP (Five K. pneumoniae, 2 E. cloacae and 1 C. 
freundii). Despite having been present in Singapore since 1996, no outbreak 
clone of blaIMP-1 isolates has emerged. DS6941 carried blaIMP-4 which is a 
variant that has been described in Enterobacteriaceae from Australia and 
China, and is also found in A. nosocomialis and A. pittii in this region (61, 
126, 127). The only integron sequence we were able to obtain was different 
from K. pneumoniae from São Paulo, Brazil that had blaIMP-1 –carrying 
integrons with aac(6’)-31 and aadA1, and Japanese isolates from Saitama that 
did not possess aac(6’)-Ib (128, 129). Though still relatively rare, the 
geographical distribution of Enterobacteriaceae carrying blaIMP-1 seems to 
have expanded recently (130, 131). 
 
There were 22 isolates with blaNDM (Eleven K. pneumoniae, 6. E. coli, 4 E. 
cloacae, and 1 C. sedlakii). Some of the K. pneumoniae with blaNDM-1 in our 
study belonged to ST11, ST14 and ST147 which were also the most common 
MLST types among blaNDM-1-positive  K. pneumoniae in India and the United 
Kingdom (132). Though the E. coli with blaNDM-1 from our study were diverse, 
one isolate belonged to ST101 and another to ST405 which were among the 
most common STs associated with blaNDM-1-positive E. coli in Pakistan and 
the United Kingdom (133). NDM-7 found in E. coli DM20217 is a newly 
described variant that  has been found in  E. coli from Myanmar (GenBank 
accession number AFS33103.1) and Canada (GenBank accession number 
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AFQ31613.1) and differs from NDM-1 by 2 amino acids at positions 130 (Asp 
to Asn) and 154 (Met to Leu). 
 
The c.a. 40 kb plasmid from DU43320 that was untypable by PCR based 
plasmid replicon typing has been completely sequenced and was found to be 
identical to that in DU44951 which was not successfully conjugated or 
transformed (134). These plasmids were structurally similar to an IncN2 
plasmid previously described in an E. coli from Bangladesh (135).  
 
E. cloacae DM5887-3, Citrobacter sediakii DM5680-1, together with a P. 
aeruginosa and P. putida, were isolated from an unfortunate lady who had a 
road traffic accident in India, where she was initially hospitalized before being 
transported back to Singapore. After we completed this study, a K. 
pneumoniae (DM10361 see Figure 15) with blaNDM-1 was also subsequently 
isolated from this patient. All three Enterobacteriaceae carried blaNDM-1 on 
plasmids of different sizes. The two Pseudomonads were also positive for 
blaNDM-1 but the gene did not appear to be plasmid-borne. This case illustrates 
well the ability of blaNDM-1 to infiltrate into different bacterial species. 
  
There were 4 K. pneumoniae with blaOXA-181 and they were all clonal by 
PFGE. In our isolates, blaOXA-181 gene was localized to a large plasmid that 
was not able to conjugate or transform. By contrast a small c.a. 7 kb plasmid 
bearing blaOXA-181 that was also not transferable by conjugation has been 
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described from K. pneumoniae isolated in Oman and the United Kingdom, 
associated with travel to India (53, 136).   
 
Both isolates with blaOXA-48 were isolated from Singaporeans. This is the first 
time this carbapenemase gene has been detected from isolates in Southeast 
Asia. We are uncertain how blaOXA-48 entered Singapore as we were unable to 
obtain a history of recent travel from the patients and neither isolate belonged 
to MLST clones that have been associated with outbreaks in other countries. 
The c.a. 50 kb plasmid with blaOXA-48 in K. pneumoniae DU20470-1 and E. 
coli DB4758 that was untypable by PCR based plasmid replicon typing may 
be distinct from the c.a. 62 kb IncL/M plasmid that has disseminated in 
Europe, the Middle East, and North Africa (137). Plasmids of this size bearing 
blaOXA-48 have also been described in the United Kingdom (136).  
 
blaOXA-181 and blaOXA-48 have been associated with ISEcpI and IS1999 
respectively (53, 138). Our inability to sequence the flanking regions to these 
genes in our isolates further suggests that the origin of these isolates may be 
different from those already described. 
 
There were 3 K. pneumoniae, 1 E. coli, and 1 E. cloacae with blaKPC-2. K. 
pneumoniae with blaKPC-2 have previously described in Singapore by Balm et 
al (139). Those isolates were clonal, belonged to ST11, and the sequences 
flanking blaKPC-2 were identical to that of pKP048 from China. In our study, 
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all 3 K. pneumoniae with blaKPC-2 had distinct PFGE patterns.  One isolate, 
DB2244 had an identical PFGE pattern to those in the previous study 
(personal communication Dr Jeanette Teo). The flanking regions of blaKPC-2 
for DB2244 were also similar to that reported in K. pneumoniae KP048 
plasmid pK048. In the remaining isolates, the flanking regions of blaKPC-2 
included a truncated blaTEM gene upstream, and were similar to that reported 
as Variant 1 by Shen et al (121). In these isolates blaKPC-2 was carried on an 
identical c.a. 50 kb plasmid that was untypable by plasmid replicon typing. 
 
In 1996, Singapore became one of the first countries to isolate a plasmid-
mediated carbapenemase-producing Enterobacteriaceae (CRE). However, the 
expected increase in carbapenem resistance did not occur until 2010.  The first 
carbapenemase gene to be described locally, blaIMP-1, failed to become a 
significant problem despite the fact that it is established in P. aeruginosa in 
Singapore (59). The present diversity of carbapenemase genes reflects 
Singapore’s geographical location at an international crossroads in proximity 
to India, China, Australia, and Japan as well as its role as a hub for 
international travel. 
 
The recent increase in Enterobacteriaceae with carbapenemase genes 
coincides with their discovery overseas. This is clearly linked to importation 
from overseas in the cases of blaNDM-1, and blaOXA-181, though recent isolates 
have not been obviously imported. The point when blaIMP, blaOXA-48 and 
blaKPC-2 entered Singapore is not obvious. The association with carbapenem 
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usage is also unclear. Carbapenem prescriptions have only increased slightly 
in Singapore overall. However, there has been increased use of ertapenem and 
meropenem at the expense of imipenem (140).  The findings of this study 
underscore the need for systematic molecular surveillance to fully understand 





Chapter 5 Discussion 
 
A brief reprise of themes introduced in the opening chapter 
Carbapenemase-producing (and by implication multidrug-resistant) Gram-
negative bacilli are becoming an increasing problem worldwide. Initially the 
problem was largely confined to P. aeruginosa and A. baumannii, pathogens 
already possessing a predisposition to develop resistance to any antimicrobial 
agent. Infections with these pathogens were usually limited to nosocomial 
settings like the intensive care unit where carbapenem use was heavy and the 
patients had compromised immune systems. However in the last decade there 
has been a dramatic increase in carbapenemases among the hitherto unaffected 
Enterobactericeae (141).  Because these bacteria are involved in a wider range 
of infectious diseases, the scope of infections that are difficult to treat with 
available antimicrobials has increased. Furthermore, CRE have been found in 
the environment, raising the spectre of untreatable infections presenting from 
the community (37).  
 
The problem is being compounded by the lack of readily available 
alternatives. Much attention in the recent past has been focussed on 
antimicrobial resistance in Gram-positive pathogens like penicillin-resistant 
Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and  
glycopeptide-resistant Enterococci. This has led to a flurry of drug 
development resulting in new antimicrobials like daptomycin, linezolid, 
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telavancin, ceftaroline, and quinoprostin-dalfopristin (142). Drug development 
for multidrug-resistant Gram-negative bacilli has been slower and much less 
productive. The first really new drug to reach the formulary was tigecycline. 
However susceptibility may be variable and its efficacy in severe infections 
has been questioned (143).  Desperate clinicians have had to resort to 
combination therapy, often including older antimicrobials like fosfomycin and 
the polymixins, guided by little or no evidence (144).  
 
In the introductory chapter we introduced the theme of how each time a new 
antimicrobial is introduced, the bacteria have been able to respond with an 
appropriate resistance mechanism.  In fact carbapenem resistance may arise 
due to a variety of mechanisms. Carbapenem resistance in P. aeruginosa is 
often the result of multi-drug efflux in combination with impermeability in the 
presence of continued expression of the chromosomal cephalosporinase (27). 
These potential mechanisms of carbepenem resistance are intrinsic to every 
isolate of P. aeruginosa. Of the 123 isolates of imipenem-resistant P. 
aeruginosa isolated in 2008, less than 10% were carbapenemase positive 
implying that intrinsic mechanisms accounted for the majority of carbapenem 
resistance.  Similarly, a combination of extended-spectrum or pAmpC  β-
lactamase hyper-production and diminished porin expression may lead to 
carbapenem resistance in Enterobacteriaceae (145). These mechanisms were 
likely to be responsible for many of the initial isolates of CRE in Singapore. 
Between 2004 and 2006, 40% of the carbepenem-resistant K. pneumoniae 
possessed the gene for the pAmpC β-lactamase DHA-1 (69). Of six 
carbapenem-resistant E. coli isolated between 2006 and 2008, all possessed 
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either the gene for the pAmpC β-lactamase CMY-2, the gene for a CTX-M-
Group 1 ESBL, or both (unpublished data). Nevertheless, the acquired 
carbapenemases represent a very different and specific response to 
carbapenems as neither the intrinsic mechanisms of carbapenem resistance in 
P. aeruginosa nor the pAmpC and ESBLs in Enterobacteriaceae are 
transferable mechanisms of carbapenem resistance. In the first chapter, a 
variety of acquired carbapenemases was introduced.  The data presented in 
this thesis shows that all major acquired carbapenemase genes can be found in 
Singapore (see Table 19). This is a remarkable variety of resistance 
mechanisms for a small country. By comparison, South Korea with a 
population 10 times larger but more homogenous than that of Singapore, has 
reported 6 acquired carbapenemases (VIM-2, IMP-6, OXA-23, NDM-1, KPC, 
SIM-1) among Gram-negative bacilli (146).  
 
Table 19 Acquired carbapenemase genes found in Singapore. 
Carbapenemase gene Species Reference 


















K. pneumoniae This study 
blaIMP-26 P. aeruginosa (148) 
blaVIM-2 P. aeruginosa (148) 
blaVIM-6 P. putida (60) 














blaNDM-7 E. coli This study 










blaOXA-181 K. pneumoniae (150) 




blaOXA-27 A. baumannii (152) 






blaOXA-96 A. baumannii (61) 
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We began this study by looking at the two most common carbapenem-resistant 
pathogens in Singapore, P. aeruginosa and Acb.  During the course of our 
investigations, we were also able to witness at first hand the emergence of a 
new threat of carbepenem-resistance in the Enterobactericeae and this was 
incorporated into the study. 
 
In general, two layers of molecular typing were employed. The first layer was 
a more discriminatory fingerprinting method used to determine the presence of 
clones within the local population of isolates. In the case of P. aeruginosa and 
the Enterobacteriaceae we used PFGE. For A. baumannii we used RAPD-
PCR rather than PFGE because it is a rapid, economical, standardized 
fingerprinting method for A. baumannii. There is no equivalent standardized 
PCR method for fingerprinting P. aeruginosa and Enterobacteriaceae. PFGE 
is more expensive, time-consuming and tedious to perform compared with 
PCR methods. The advantages of PFGE are better reproducibility and perhaps 
better discrimination. In retrospect, it is possible we would have obtained 
better data using PFGE instead of RAPD-PCR for fingerprinting A. 
baumannii. Both these typing methods allow good discrimination between 
isolates for the investigation of outbreaks but do not allow for inter-laboratory 
comparisons. 
 
From the fingerprinting data, representative isolates were selected for a second 
layer of typing. This was primarily MLST. Whilst poor at defining outbreaks, 
this method being sequence-based is objective, transferable and allows inter-
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laboratory comparisons. For A. baumannii AFLP™ was also performed 
because some of the initial designation of International clones was done by 
AFLP™, which preceded the use of MLST for categorizing this species. 
 
The characterization of CRE was more detailed. This included trying to 
sequence the flanking regions of carbapenemase genes and characterization of 
the plasmids. This extra effort was justified because whereas carbapenemase-
producing P. aeruginosa and Acb have been around for longer and their 
genetic frameworks are relatively established, CRE are a very new worldwide 
phenomenon and much less is known. 
 
Major findings regarding acquired carbapenemases in P. aeruginosa 
The percentage of carbapenemase-producers among carbapenem-resistant P. 
aeruginosa in 2008 had not increased compared to an earlier study carried out 
in 2000 (59). This suggests that the situation in P. aeruginosa has stabilized, 
though a caveat is that the sample size is rather small. In the 2000 study, there 
were two clones. One clone had blaIMP-1 that had a nucleotide sequence 
identical to the original first reported from Japan (33). The other clone had 
blaIMP-1v, a sequence variant that differed from the original by four silent 
mutations. This particular sequence variant has so far only been described in 
Singapore to date. Neither clone had emerged dominant in 2008 though both 
variants of blaIMP-1 were still found. Instead the 2008 isolates were quite 
heterogenous with blaVIM-2 and blaVIM-6 emerging in P. aeruginosa for the first 
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time in Singapore. Two related isolates in 2008 had blaIMP-7, but were distinct 
from the blaIMP-7-positive isolate from 2000. A novel MBL blaIMP-26 that is 
related to blaIMP-4 was also described. The two clones from 2000 belonged to 
ST964 (CC654) and ST233 (CC233). Some isolates in 2008 belonged to these 
clonal complexes but had different STs and slightly different PFGE patterns. 
The distribution of blaIMP-1 variants between the two clonal complexes 
remained consistent from 2000 to 2008.  Only isolates from 2008 belonged to 
CC235 and they contained a mix of MBL genes.  
 
Major findings regarding acquired carbapenemases in Acb 
This study was in two parts. The first was a cross-sectional snap-shot of Acb 
isolated in public hospitals over 1 month in 2006. This showed that A. 
baumanni was the most common (78.7%) followed by A. nosocomialis 
(11.9%), and A. pittii (9.3%). Carbapenem resistance was highest in A. 
baumannii (72.4%) but was also significant in A. pittii (27.8%) and A. 
nososcomialis (34.8%). Most carbapenem-resistant A. baumannii and A. 
nosocomialis possessed the blaOXA-23-like gene which was usually preceded by 
ISAba1. Most carbapenem-resistant A. pittii had the blaOXA-58-like gene which 
was sometimes preceded by ISAba3. One A. baumannii and one A, 
nosocomialis also had blaIMP-like genes. 
 
The second part of the study was a typing exercise on a limited number of 
isolates from 2006, and from the archive collection of Hospital S.  The main 
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outbreak clone of A. baumannii from Hospital S in 1996 that contained 
blaOXA-66 belonged to ST25. Another outbreak clone from 1996 that contained 
blaOXA-88 belonged to novel ST111. Both had AFLP™ profiles that were 
unrelated to European (International) clones I-III. The main outbreak clone 
from Hospital S in 2001 contained blaOXA-64, and belonged to European clone 
II and ST2. Related isolates could still be found in this hospital in 2006. 
Another outbreak clone from Hospital S in 2001 containing blaOXA-69 belonged 
to European clone I and ST1. A number of isolates collected from other 
hospitals in 2006 also belonged to European clones I and II. 
 
Major Findings regarding acquired carbapenemases in 
Enterobacteriaceae  
This study is the first to document the appearance of blaIMP-4, blaNDM-1, 
blaNDM-7, blaOXA-181, and blaOXA-48 in Singapore. Acquired carbapenemases 
were found mainly in K. pneumoniae followed by E. coli. Although blaIMP-1 
was the first carbapenemase gene to be described in Enterobacteriaceae in 
Singapore it has not become established in large numbers. Most CRE were 
isolated from 2010 onwards. The largest group were Enterobacteriaceae that 
carried blaNDM-1.The only large outbreak clone was blaOXA-181-positive K. 
pneumoniae that were related by PFGE to some isolates with blaNDM-1. These 
isolates belonged to ST14. A number of K. pneumoniae with blaNDM-1 also 
belonged to one of two small PFGE clusters corresponding to ST273 or 
ST147. Even though K. pneumoniae with blaKPC-2 were not clonal by PFGE, 
they all belonged to ST11. Carbapenemase-producing E. coli and E. cloacae 
were not related by PFGE. A c.a. 150-160 kb plasmid bearing blaIMP-1 and 
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belonging to plasmid replicon type A/C was common to three K. pneumoniae 
and one C. freundii isolate. A c.a. 40 kb untypable plasmid bearing blaNDM-1 
was common to three K. pneumoniae and one E. cloacae isolate. A c.a. 150 kb 
type A/C plasmid with blaNDM-1 was found in an E. cloacae and E. coli. 
blaOXA-181 was found on a c.a. 150 kb plasmid that was not transferable. 
blaOXA-48 was found on identical untypable plasmids in E. coli and K. 
pneumoniae. The flanking regions of blaKPC-2 resembled those of strains in 
China. These sequences were found on identical c.a. 50 kb plasmids that were 
untypable. 
 
The role of international outbreak clonal complexes 
All three studies show the recent influence of international outbreak clonal 
complexes. Though the individual isolates may be unrelated by discriminatory 
fingerprinting methods, these clonal complexes represent evolutionary 
lineages that have successfully disseminated in other countries.  
 
Internationally, clonal complexes CC111 and CC235 dominate among MBL-
producing P. aeruginosa (153), though ST621 has also been associated with 
international dissemination of blaIMP-13 (154). ST235 was the most common 
sequence type among IMP-producing P. aeruginosa in Japan (155) and Korea 
(156), though it was also found among European isolates producing VIM-type 
MBLs (157). On the other hand, CC111 was largely confined to Europe. VIM-
2-producing P. aeruginosa causing an outbreak in an Italian Hospital belonged 
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to ST111 (158). Nationwide surveillance of Dutch hospitals in 2010-2011 
found that the majority of VIM-2-producing P. aeruginosa were ST111 (159). 
The outbreak isolates from Singapore in 2000 did not belong to either of these 
clonal complexes. Furthermore, these sequence types have not persisted 
locally nor have they been documented to have caused outbreaks overseas. 
ST235 isolates only appeared in Singapore from 2008. These isolates carried a 
variety of MBL genes and no clone had emerged at the time of the study. 
 
Like the P. aeruginosa, the original carbapenemase-producing A. baumannii 
in Singapore did not belong to any of the European (International) clones I-III. 
These clones initially defined by AFLP™ correspond to MLST clonal 
complexes CC1-3 in the Institute Pasteur Scheme. CC1 and CC2 are 
responsible for much of the spread of carbapenemase-producing A. baumanii 
globally (160). This is possibly because they are very successful vehicles for 
the carriage of blaOXA-23 (93).  However in Italy, carbapenem resistance in A. 
baumannii was mostly due to blaOXA-58 rather than blaOXA-23. The most 
widespread clone blaOXA-58-positive ST4 (CC92) found in 5 Italian hospitals 
was related to International Clone II (161).  Isolates belonging to these clonal 
complexes only started to appear in Singapore from 2001. There were no 
representatives from CC3 which seems to be localized to Europe (160).  
 
Unlike P. aeruginosa and A. baumannii, the appearance of carbapenemase 
genes in Enterobacteriaceae in large numbers is fairly recent. As our study 
shows, the ability of some of the plasmids bearing blaIMP-1, blaNDM-1, blaKPC-2 
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and blaOXA-48 to readily transfer between strains means that resistance 
continues to spread without the need for epidemic clones of bacteria. 
Nevertheless, there are particular clones of Enterobacteriaceae that are 
notable for spreading antimicrobial resistance. K. pneumoniae ST258 is 
associated with the spread of blaKPC-2 in North America, Israel and Europe 
(162). On the other hand, the spread of blaKPC-2 in China, Taiwan and 
Singapore is largely due to ST11 (139, 163, 164). ST11, ST14 and ST258 
together form one large clonal complex (CC292) responsible for the global 
spread of diverse resistance elements including extended-spectrum β-
lactamases, blaNDM-1, and blaVIM-1 (165).  Despite being the first acquired 
carbapenemase gene to be found in Enterobacteriaceae in Singapore, blaIMP-1 
has not become established. While the exact reason for this remains unknown, 
it could have something to do with the fact that plasmids bearing this gene 
have been relatively unsuccessful at entering strains belonging to international 
outbreak clonal complexes. 
 
There was no outbreak clone of E. coli in our study though some isolates 
belonged to international clones. E. coli ST101, ST648 and ST405 have been 
associated with spread of blaNDM-1 in England and Pakistan (133). Individual 
cases of blaNDM-1-positive E. coli ST101 and ST405 have also been imported 





The results for A. baumannii and P. aeruginosa illustrate the point that 
bacteria may undergo significant shifts in the population which will not be 
revealed without the application of molecular typing methods like MLST. The 
recent increase of international clones in these two species taken together with 
the MLST results for Enterobacteriaceae suggest a greater role for overseas 
travel in the spread of carbapenemase genes into Singapore since the 




Diversity of acquired carbapenemases found in Singapore 
The diversity of acquired carbapenemases found in Singapore seems to reflect 
the geo-economic contacts with other countries though there are some 
inconsistencies. The situation in Singapore is very similar to that of Japan 
where blaIMP-1 may be found in P. aeruginosa and K. pneumoniae. However in 
Japan, blaIMP-1 is regularly found in S. marcescens (169), whereas it is has 
never been described in this species in Singapore. Similarly blaIMP-1 in Korea 
has spread between Pseudomonas spp. and Acinetobacter spp. (170) whereas 
this gene has not really penetrated into Acinetobacter spp. in Singapore despite 
the fact that this species is often found on the same patients who are likely to 
harbour carbapenemase-producing P. aeruginosa. Comparing the few 
integrons we have been able to sequence, there seems to be an increase in the 
number of gene cassettes with resistance determinants going from 
environmental fluorescent Pseudomonas spp. to P. aeruginosa and K. 
pneumoniae. The numbers are too small but this would be in keeping with a 
reservoir of blaIMP-1 in environmental Pseudomonas spp. 
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Figure 29 Gene cassettes inserted into integrons which contain blaIMP-1. 
 
 
IMP-4 has 95.6% homology with IMP-1. blaIMP-4 was first described in 
Citrobacter youngae in China (127) and non-baumannii Acb in Hong Kong 
(75). It has subsequently appeared sporadically in a diversity of Gram-
negative bacilli in Australia (126) and Acinetobacter spp. and P. aeruginosa in 
Malaysia (171, 172). blaIMP-4-positive K. pneumoniae were recently isolated 
from three patients with no travel history in the United States and appears to 
be spreading in China (173-175). Unusually, the American and Chinese 
isolates were from children. blaIMP-4 was first found in Singapore in 
Acinetobacter spp. isolated in 1996 (61). Three of the four strains were 
isolated from haematology patients from Indonesia.  Although we have since 
also found blaIMP-4 in K. pneumoniae, it is unlikely that inter-species transfer 
has occurred. The flanking sequences of blaIMP-4  in Acinetobacter spp. 
showed a class I integron that contained in order blaIMP-4, qacG, aacA4 and 
catB3 (61). This order of genes was identical to that of Acinetobacter spp. 
from Hong Kong and K. pneumoniae from Australia. However, for the 
Singapore K. pneumoniae isolate, we were only able to obtain the sequence 
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upstream of blaIMP-4 which showed the presence of a class I integron. We were 
unable to obtain the downstream flanking sequence despite repeated attempts 
suggesting some disruption of the 3’ non-variable region of the integron. 
 
While blaIMP-1 seems likely to have originated from Japan and blaIMP-4 from 
China, the distribution of blaIMP-7 is more difficult to explain. IMP-7 shares 
>86% amino acid identity with other IMP enzymes. It was first reported in 
Canada followed by Malaysia and seems established in these 2 countries (176-
179). The Canadian isolates had the integron structure orf1, aacC4, blaIMP-7, 
aacC1. In 2004, Singapore became the third country to report blaIMP-7-positive 
P. aeruginosa (59). The 3 isolates described so far belong to different 
sequence types ST744, ST745 and ST235 (though ST745 is a single locus 
variant of ST235) (148). The ST744 isolate from 2000 had the integron 
structure blaIMP-7, aacC1 (GenBank accession number AY625685.1) whereas 
the ST745 isolate from 2008 had the integron structure blaIMP-7, aacA4, aadA2 
(unpublished data). Japan first reported a case of blaIMP-7 in 2007. The patient 
had been in hospital in Singapore prior to returning to Japan (79). However a 
subsequent report from another part of Japan with five isolates suggests that 
this gene may have been in the country before. Two different integron 
structures were described, one with blaIMP-7, aadA6, orfD and the other blaIMP-
7, aacC4, aadA2 (180). Surprisingly blaIMP-7 has surfaced in Eastern Europe. 
The majority of MBL-producing P. aeruginosa in Slovakia in 2006 were 
positive for blaIMP-7 (181). Subsequently, a clone of ST357 P. aeruginosa has 
spread in Poland and the Czech Republic with an integron structure 
comprising of aac(6’)-Ib (aacA4), blaIMP-7, aac(3)-I (aacC1) (182). It is worth 
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noting that to date, unlike some of the other blaIMP genes, all blaIMP-7 have only 
been reported in P. aeruginosa. The diversity of sequence types and integron 
structures suggests that the American, European and Asian clones are distinct. 
 
VIM-6 was first described in two P. putida isolated in Singapore in 2000 (60). 
The amino acid sequence is 99.2% identical to the closely related VIM-2 and 
VIM-3. The gene was found on a class I integron with the structure blaVIM-6, 
blaOXA-10, aacA4, orf, aadA1 (183). In this study we isolated a single P. 
aeruginosa belonging to ST746 with blaVIM-6 in 2008. The integron structure 
was blaVIM-6, aacA7, aadB (unpublished). Since blaVIM-6 had not been reported 
in any other country in the period from 2000 to 2008, it would have been easy 
to conclude that this gene originated from Singapore. One of the problems 
with trying to form conclusions based on molecular epidemiology studies is 
the issue of investigator bias. The distribution of antimicrobial resistance 
determinants around the world is heavily correlated with the presence of 
individual investigators in these countries with a research interest in this field. 
Conversely, there are enormous gaps in knowledge about countries where 
such research has not been carried out. In 2010, Castanheira et al reported the 
widespread distribution of blaVIM-6 in MBL-producing P. aeruginosa in India 
collected in 2006 (184). They subsequently also found blaVIM-6 in P. 
aeruginosa from Indonesia, Korea, and the Philippines (185). Two types of 
integron structures were described. A 5 kb integron identical to that first 
reported in P. putida from Singapore was found in isolates from Korea, 
Indonesia and India. A smaller 3.9 kb integron with blaVIM-6, blaOXA-10, and 
aacA4 was found in isolates from the Philippines and India. 
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blaNDM-1 and blaOXA-181 were very clearly imported to Singapore from the 
Indian subcontinent as the entry of these genes into Singapore was temporally 
linked to the global expansion of their range and we were able to clearly 
identify the initial imported cases (149, 150). The molecular epidemiology of 
K. pneumoniae with blaKPC-2 suggests China (ST11) as the source rather than 
Europe or the United States (ST258). However, in this case we were unable to 
ascertain how or when this gene entered Singapore. The appearance of blaOXA-
48 was not anticipated as Singapore does not have such close links to Turkey or 
North Africa where this resistance determinant is usually found. The 
molecular epidemiology of our isolates (K. pneumoniae ST29, plasmid 
untypable) also does not fit with the outbreak stains from these countries 
(ST395, IncL/M) (137). It is possible that this resistance determinant was 
imported from an as yet unrecognized source country. 
 
As we try and draw conclusions about how acquired carbapenemase genes 
have entered Singapore, it is worth noting that while some genes have been 
successfully imported, others have not. blaVIM-1 is a major cause of 
carbapenem resistance in the European Mediterranean (35). Its absence here 
can be explained by the geo-political disconnection with Singapore. It is less 
easy to explain the paucity of blaVIM-2 which is probably the most widely 
distributed MBL worldwide. blaIMP-6 like blaIMP-1 is found in both Japan and 





The nature of spread and implications for infection control 
The spread of acquired carbapenemase genes may be the result of a number of 
different mechanisms. These include the spread of resistance determinants into 
the circulating bacterial population, or direct human-mediated dispersal of 
clones with properties that promote their spread. The distinction between the 2 
is that clonal spread may be more rapid and driven by specific selection 
pressures like antibiotic use, whereas spread of resistance determinants 
continues at a steady pace even without selection as genes are apparently quite 
regularly exchanged between bacteria (187). 
 
The outbreak strains of P. aeruginosa and A. baumannii seem to be related to 
the presence of specific clones. The P. aeruginosa clones from 2000 and the 
A. baumannii clones from 1996 did not persist suggesting that infection 
control measures based on limiting human-mediated spread may be useful, 
though in the case of A. baumannii it is also possible that they were 
outcompeted by global clones. 
 
The situation in Enterobacteriaceae may be more complex. blaOXA-181 seems 
to be mainly spread by a specific clone. On the other hand, blaKPC-2, blaNDM-1, 
and blaOXA-48 are found on plasmids that freely conjugate. The plasmids 
bearing blaNDM-1 are particularly promiscuous and when newly introduced to a 
population, the host bacteria are liable to show diversity. Inevitably however, 
some will eventually enter host bacteria that spread clonally as has happened 
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in the case with blaKPC-2 (139). In a recent outbreak at a Canadian tertiary care 
centre, transmission of two clones of blaNDM-1 –positive K. pneumoniae was 
terminated by implementation of contact precautions, screening of contacts, 
and environmental disinfection (188). In 2006, a nationwide clonal outbreak of 
blaKPC-3-positive K. pneumoniae in Israel required a national response when 
local measures failed. The investigators in that outbreak attributed their 
success to a combination of standard precautions, contact isolation, and the 
assignment of dedicated nursing staff (189). There is less experience 
successfully controlling the spread of resistance plasmids as opposed to 
bacterial clones. It seems plausible that environmental cleaning and 
antimicrobial stewardship may have a more important role to play in these 
situations though there is precious little evidence to support any specific 
measure as being effective. However hospital infection control efforts will be 
to no avail if a large reservoir of resistance genes exists beyond the hospital 
boundary. In 2000, the same clone of IMP-1-producing P. aeruginosa was 
found in both acute and step-down community hospital in Singapore (59). 
Carbapenemase-producing K. pneumoniae have been also found in the 
community and in nursing home residents in other countries (190). We are not 
sure when blaKPC-2 entered Singapore but the presence of a common PFGE 
type in patients with no epidemiological linkage in 3 different hospitals 
suggests there is a hidden reservoir that remains to be discovered (139). 
 
Finally, it is worth taking a step back and evaluating the acquired 
carbapenemase that Singapore has arguably had the most experience with.  
blaIMP-1-positive K. pneumoniae was first discovered in Singapore in 1996 
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(58). This was one of the first descriptions of an Enterobacteriaceae 
producing an acquired carbapenemase. blaIMP-1 is also established in  P. 
aeruginosa locally (59). When these results were first published, it was 
anticipated that a wave of CRE would follow (58). To a large extent, this has 
failed to materialize, despite the fact that blaIMP-1 has clearly been circulating 
in the background all this time and the c.a. 150-160 kb plasmid carrying the 
gene seems quite capable of transferring between strains. There have been no 
local outbreaks of blaIMP-1-positive Enterobactericeae and the number of 
isolates remains relatively small. The impact of this gene among 
Enterobacteriaceae at least is perhaps less than what was originally expected. 
 
Unanswered questions and future work 
The blaNDM-1 and blaOXA-181 genes are thought to have originated from 
Acinetobacter spp. (191) and  Shewanella xiamenensis (192) respectively. 
Their entry into Singapore seems clearly linked to the importation of 
Enterobactericeae carrying these genes (149, 150). Paradoxically, less is 
known about the origins of blaIMP-1.  The environmental source of this gene 
still remains to be discovered. Was blaIMP-1 imported into Singapore from 
Japan in the past or is there a common environmental source in these two 
countries? The presence of blaIMP-1 in simple integrons in environmental 
Pseudomonads seems to point to the latter but the relatively limited 
distribution range of blaIMP-1 to countries with geo-economic links to Japan 




What makes some clones more successful at spreading globally than others? 
Why did some clones cause local outbreaks where others failed? Possible 
explanations that remain to be proven include stochasticity or genes/factors, 
other than antimicrobial resistance, that promote their survival and spread. 
  
Finally, there is the question as to why this is all happening now. Imipenem 
was officially introduced to the Singapore General Hospital in June1998. This 
was followed by meropenem in February 2000, ertapenem in October 2003, 
and Doripenem in March 2012 (Personal communication Ms Winnie Lee, 
Department of Pharmacy, Singapore General Hospital). During this period, 
carbapenem usage has steadily increased exerting a corresponding 
antimicrobial pressure on the bacterial population. However this does not 
explain everything because increased carbapenem usage only led to a slight 
increase of carbapenem-resistant Acb and no increase of carbapenem-resistant 








Another contributing factor may be the increase in medical tourism. In 2007, 
Singapore received 571,000 foreign patients mainly from Indonesia, Malaysia 
and the Middle East (194) . Singapore had set a target of attracting 1 million 
foreign patients by 2012 (195). Given that many of these patients are likely to 
come from countries with high levels of antimicrobial resistance, Singapore 
must remain vigilant to avoid becoming a mixing vessel for antimicrobial 
resistance determinants and eventually a net exporter of multidrug-resistant 
bacteria. In addition, the majority of foreign patients attend private hospitals. 
The private sector therefore represents a potential ‘blind corner’ as the 
microbiology laboratories of these hospitals often run without doctorate-level 






























laboratories. There is a danger that in private laboratories, multidrug-resistant 
bacteria may either remain undetected or their significance unappreciated. 
 
A complex picture emerges with interplay between antimicrobial usage, 
increased importation as a result of foreign travel and medical tourism, and the 
intrinsic properties of particular clones and transmissible resistance elements 
that favour spread. The future trend is likely to be bleak, especially for CRE.  
Some of the global clones of Enterobacteriaceae that carry carbapenemase 
genes are the same ones that harbour CTX-M ESBL genes. First described in 
the late 1980s, CTX-M-producing Gram-negative bacilli spread rapidly in the 
mid-1990s to become the dominant mechanism for oxyimino-cephalosporin 
resistance worldwide today (196).   Both blaNDM-1 and blaKPC-2 have been 
found in the environment (37, 197). There is therefore the possibility that 
CRE, like CTX-M and pAmpC-producing Enterobacteriaceae, may 
eventually enter into the food chain where resistance is driven by even greater 
antimicrobial use (198, 199). This is important because some of the countries 
with significant problems with CRE (India and China) are also major 
exporters of raw food into Singapore (200). Future lines of research include 
determining which elements of spread are most important and the most 
effective infection control measures. The environmental reservoirs of some 
carbapenemase genes like blaIMP-1 still remain to be discovered.  The 
introduction of newer and even more detailed methods of typing like whole 




There are a number of weaknesses in the studies in this thesis. Firstly, the 
numbers of isolates were relatively small and in the cause of P. aeruginosa 
and Enterobacteriaceae, only one hospital was represented. However, 
Singapore is a small country with a mobile patient population, so the regional 
differences between one hospital and another may be less than in larger 
countries. Second, the isolates were not systematically collected but 
represented random collections at different time intervals. This was partly 
governed by the grants available at the time. Third, resources did not permit 
the collection of more clinical epidemiology data from the patients which 
would have helped correlate the molecular epidemiology work on the isolates. 
Finally, the P. aeruginosa and Acb work was done earlier and the situation 
may have changed. This is especially relevant for the newly introduced 
blaNDM-1 and blaKPC-2 which have been known to spread in these two species 
(202, 203). This illustrates the constantly changing landscape that is the field 
of antimicrobial resistance epidemiology and emphasizes the importance and 
continued need for surveillance. This should be done in a regular, systematic 
fashion fully funded at the national level. To achieve this, the Ministry of 
Health in Singapore has created a National Public Health Laboratory which 
tests for novel antimicrobial resistance determinants and a National 
Antimicrobial Taskforce which conducts surveillance of antimicrobial 
resistance of key pathogens. However the molecular typing of important 
multidrug-resistant bacteria is not routine. Given the known potential for 
antibiotic resistance determinants to enter into the food chain, veterinary and 
food surveillance would be prudent and there should be more co-operation 
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The aim of this thesis was to identify the reasons behind the increase in 
carbapenem-resistance in Gram-negative bacilli in Singapore. The hypothesis 
was that this was the result of the introduction of global clones with the 
potential to cause outbreaks. 
 
This hypothesis is only partially proven possibly because the situation may be 
in transition. For P. aeruginosa and A. baumannii, only local clones were 
present in the earlier isolates collected in 2000 and 1996 respectively. Global 
clones for P. aeruginosa (ST235) emerged in the isolates collected in 2008 but 
were heterogenous and did not cause local outbreak clusters. Furthermore, the 
carbapenemase-producers only represented less than 10% of P. aeruginosa 
that were resistant to imipenem suggesting that most of the carbapenem 
resistance in this species may be driven by other mechanisms like AmpC 
hyper-production in combination with porin loss. In summary, global clones of 
carbapenemase-producers have recently emerged in P. aeruginosa in 
Singapore but carbapenemase-producing P. aeruginosa did not pose a 




Global clones of A. baumannii (ST1 and ST2) were found in both the 2001 
and 2006. Unlike P. aeruginosa, almost all carbapenem-resistant A. baumannii 
were carbapenemase-producers. In 2001, global clones of A. baumannii cause 
local outbreak clusters and at least one of these clones persisted in one hospital 
to 2006. Therefore global clones are likely to have played a role in the high 
rates of carbapenem-resistance among A. baumannii in Singapore. 
 
Unlike the other 2 species, carbapenem-resistance in Enterobacteriaceae is a 
relatively new phenomenon. The situation is also confused by the ability of 
some of the carbapenemase genes to be easily transferred via plasmids. 
Nevertheless, some global clones were found (ST11 and 14 in K. pneumoniae 
and ST101 and ST405 in E. coli). Perhaps the reason why blaIMP-1 has not 
become as widespread as originally anticipated is due to the fact that it is not 
commonly found in one of these global clones. While the numbers are 
presently relatively small, with blaKPC-2, blaOXA-181, and blaNDM-1 found in 
global clones, an increase in CRE is likely in the future. 
 
These studies show the diversity of acquired carbapenemase genes in 
Singapore, their distribution among different species, and the mechanisms 
underlying their spread. Little is known about the molecular epidemiology of 
multidrug resistance in Gram-negative bacilli in Southeast Asia. These studies 
have contributed to the general body of knowledge about the worldwide 
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Appendix 1 Buffers for PFGE 
 
1) PIV Buffer 
 
1M Tris pH 8.0 
1M Tris pH 8.0   60.55 g 
Clinical Lab Reagent Water  400 ml 
Concentrated HCl   ~21 ml (adjust to pH) 
 
PIV Buffer 
1M NaCl     29.22 g 
1M Tris, pH 8.0   1 ml 
Clinical lab reagent water  500 ml 
 
2) EC Buffer 
 
0.5 M EDTA pH 8.0 
Na2EDTA.2H2O   93.05 g 
160 
  
Clinical lab reagent water  400 ml 
NaOH pellets    10 g 
 
EC Lysis buffer 
0.5 M EDTA pH 8.0   100 ml 
1M Tris pH 8.0   3 ml 
1M NaCl    29.2 g 
Sodium deoxycholate   1 g 
N-laurylsarcosine sodium salt 2.5 g 
Clinical lab reagent water  ~400 ml 
 
3) ES Buffer 
Na2EDTA.2H2O   93.1 g 
Clinical lab reagent water  500 ml 
NaOH pellets    ~10 g 




Appendix 2 Buffers for AFLP™ 
 
1) Lysis Buffer 
Guanidine-iso-thiocyanate  120 g 
0.1 M Tris-HCl (pH 6.4)  100 ml 
0.2 M EDTA (pH 8.0)  22 ml 
Triton X-100    2.6 g 
Dissolve at 65ºC.  Keep in the dark. 
 
2) Wash Buffer 
Guanidine-iso-thiocyanate  120 g 
0.1 M Tris-HCl (pH 6.4)  100 ml 




Appendix 3 Comparison of Acb strains from Singapore with reference 
strains by AFLP.  
 




















































































































































































































































































































































































Genomic species 13TU 
Genomic species 3 
A bereziniae 
Strain Specimen no. Hospital Year
LUH 1403 DM 01197 S 2006
LUH 14035 DR 01425 S 2006
LUH 14032 TTS 6013 T 2006
LUH 14028 DB 30014 S 1996
LUH 1460 DR 25612      1996
LUH 14040 KK M3-783 2006
LUH 1404 AH 6021280795 2006
LUH 14042 AH 6011269044 2006
LUH 14045 NUH 6012 N 2006
LUH 14029 DM18619 S 1996
LUH 08397               
LUH 0839               
LUH 06125               
LUH 04621               
LUH 04624               
LUH 08402               
LUH 14613 NUH M100227   N 2006
LUH 03787               
LUH 04576               
LUH 08398               
LUH 0840               
LUH 08404               
LUH 08401               
LUH 04596               
RUH 0436               
LUH 04607               
LUH 04620               
LUH 03782               
RUH 3238               
RUH 3247               
LUH 04640               
LUH 03783               
LUH 14604 DM 18905      S 2001
RUH 3282               
RUH 0510               
RUH 3242               
RUH 3239               
RUH 2037               
RUH 0875               
LUH 06015               
LUH 06017               
LUH 05874               
LUH 05875               
LUH 06009               
LUH 06028               
LUH 06035               
LUH 06037               
LUH 06030               
LUH 14039 TTS 6023688355 T 2006
LUH 14612 NUH M96260-1  N 2006
LUH 14608 DM 02370      S 2006
LUH 14609 DM 02871      S 2006
LUH 14607 DM 01800      S 2006
LUH 14603 DU 35210      S 2001
LUH 14037 DU 05665 S 2006
LUH 05865               
LUH 06044               
RUH 3240               
LUH 06011               
LUH 06034               
LUH 06126               
RUH 3245               
LUH 05868               
LUH 06024               
LUH 06029               
LUH 04578               
LUH 04625               
LUH 03788               
LUH 04623               
LUH 04603               
LUH 04629               
LUH 08405               
RUH 0134               
RUH 3422               
LUH 06021               
LUH 14031 DM 01543 S 2006
LUH 14598 DB 24815      S 1993
LUH 14599 DM 09676      S 1996
LUH 14601 DR 25547      S 1996
LUH 14602 DR 28006      S 1996
LUH 14610 TTS 6023697393 T 2006
LUH 14611 NUH M94594-3  N 2006
LUH 14030 DU 53770 S 2005
LUH 14038 TTS 6023684721 T 2006
LUH 14041 KK M3-1097 2006
LUH 14036 DU 05219 S 2006
LUH 14605 DB 60079      S 2001
LUH 14606 DM 22501      S 2001
LUH 14046 NUH 6012570948 N 2006
LUH 14047 NUH 6012572697 N 2006
LUH 14034 DU 04461 S 2006
LUH 14043 AH 6021278593 2006
